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1.  INTRODUCTION 
 
“In the great of the Vedas, there is no touch of sectarianism. It is all ages, 
climes, and nationalities and is the royal road for the attainment of the Great 
Knowledge”.  
                                                      Thoreau, American Thinker.  
 
Siddha medicine is the oldest and the foremost medical systems in the world. 
 
“ச ொல்லிடவே வேேிக்குச்  ேொ ிேன்றொன் 
ச ொல்லவே வேேியும் நந்ேிக்குச் ச ொல்ல 
நல்லிடவே நந்ேிேன் ேந்ேிரிக்குச் ச ொல்ல 
நயமுடன் ேன்ேந்ேிரி யசுேினிக்குச் ச ொல்ல... “[2] 
_ யூகி வேத்ேிய  ிந்ேொமணி 800 
   According to Sage Yugi, the God Shiva transmitted the knowledge of 
medicine to Parvati, who in turn passed it on to Nandi, from whom it was given to the 
first practitioners of Siddha medicine the Siddhars. 
The word Siddha comes from the world Siddhi, which means an object to 
attain perfection or heavenly bliss. Siddhars were the ones who had attained „Siddhi‟ 
Siddha generally refers to Aathma Siddha that is the eight
 
supernatural 
powers. Those who attained or achieved the above- said powers are known as 
Siddhars. There were 18 important Siddhars in olden days and they developed this 
system of medicine. Hence it is called Siddha Medicine.  
The Siddha system of Medicine is Prevalent in South India, Sri Lanka, 
Malaysia, and Singapore, where the existence of Dravidian civilization was 
documented.This system owes its origin to the Dravidian culture which is of the Pre-
historic Period. [3] 
                              .          
                      .                            . 
                                               
      ,       ,                                 
   ,                                        
      .                                   
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      .[4] 
              ,                          
                                                . 
 “                     
                    
                   
                    
                     
             ” [4] 
 
                                  
                                              , 
              ,                            
                                                
              . 
 
The main aim of Siddhars was to certify that the container of the soul for the 
attainment of happiness and to reach the God. They found diseases as one of the 
obstacle to reach God. So they bestowed to the world the Siddha medicine to treat 
diseases.  
Siddhars are precise in the treatment of poisons. They identified toxic 
substances and their antidote which is documented in Siddha literature. The 
astonishing knowledge of Siddhars in herbal, metal, mineral and animal products. 
Before going to any Siddha medical Preparation, the raw drugs. Which are purified 
(detoxification) and then the purified drugs are including to the medicine.  The Signs, 
symptoms of poison in humans, the way of diagnosis of poison and treatment are 
explained in Nanju Maruthuvam (Siddha Toxicology). It contains general antidote for 
poison and treatment are explained in also the specific antidote for particular poison 
which is beneficial to the society. 
Siddha system of medicine practiced in India has a number of remedies for 
various diseases as mentioned in Siddha pharmacopoeia which includes drugs of 
herbal mineral metal and animal origin.
[5]
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In our Siddha system, they are two types of medicine which include 32 internal 
and 32 external medicines. Among 32 internal medicines, Parpam is one among them.  
From the ancient period Siddha system of traditional medicine herbo mineral 
preparation of parpam used for the treatment of various chronic ailments.Parpams are 
the powder substances obtained by calcification of purified metals, minerals and 
animal products by the specific process.They are calcined in closed crucibles in pits 
and with cow dung cakes (Pudam). Generally, this method of preparation of Siddha 
medicines involves conversation of minerals or metals into oxide or sulfide form by 
various herbal treatments followed by repeated high- temperature calcination and 
grinding cycles.
 [6]
 The parpam thus obtained constitute ultra-small particles and are 
taken along with vehicles such as milk, honey, butter, ghee etc according to diseases. 
This makes these drugs easily assailable eliminating their harmful effects and 
enhancing their biocompatibility. However very few studies have been carried out to 
understand the phytochemical nature of these type of traditional medicines for the 
metal and mineral based preparations it become improve that this drug should be 
characterized with the help of modern instrumental  techniques likely scanning 
electron microscopy (SEM), X-ray diffraction (XRD), Thermogravimetric 
analysis (TGA)
, 
etc, based on this specification of metal- based drug can be well 
standardised on a scientific basis.
  
Traditional medicines have been the important feature in human being since the 
earliest times and it has recently acquired increasing importance due to its harmless 
nature and success. 
However, these successes of our system are readily questioned by the modern 
science. The fact that the Siddha physicians use plants and chemicals such as Copper, 
Copper sulfate, mercury, arsenic, etc. which are toxic in raw form depending upon the 
dose, add weight age to this argument. This untrue belief of toxicity posing a major 
obstacle to the renaissance of Siddha medicine.   
Here, Toxicology plays its role. It is the study of the untoward effects of 
chemicals or physical agents on biological systems. The multidisciplinary nature of 
toxicology is its great strength. This can be majorly subdivided into Environmental, 
Economic, and Medical.       
Testing methods in toxicology most often involve the use of animals based on the 
hypothesis that results of toxicity studies in suitable animal models may be 
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extrapolated to humans. Over 30 countries have agreed to accept toxicity studies 
undertaken using OECD guidelines.
[7] [8]
 
The Recent interest in Traditional Medicine has taken up great dimensions in 
changing the health care scenario across the globe.The prevalence rate of varicose 
vein in India estimates 15 to 20% of a  population is suffering vein diseases.Breast 
cancer has ranked number one cancer among Indian females with the age- adjusted 
rate as high as 25.8 per 100,000 women and mortality 12.7 per 100,000 women. The 
age- adjusted incidence rate of Carcinoma of the Breast was found as high as 41 per 
100,000 women for Delhi, followed by Chennai (37.9), Bangalore (34.4) and 
Thiruvananthapuram District (33.7). The Breast Cancer year of 1975-1977 in 75%, 
the year of 1984-1986 in 79%, and the year of 1996-2004 in 89% of survival rates in 
Breast cancer.  
Tambaram is also known as „Gunmakaalan‟ [9] as it is an important prescribed 
medicine to treat gunmam in traditional Siddha system. In the present era of 
globalization for the development of a world market for traditional medicines research 
and development is Quality control of Siddha drugs are generates a lot of problems 
very essential. The present study investigate the physiochemical properties of 
traditional Indian Siddha preparation Tambira parpam which are mentioned in the 
Siddha text Theran Yamaha Venba
[10]
 widely used for treating vaginal cancer, breast 
cancer, varicose vein, skin diseases such as psoriasis, eczema, alopecia, vitiligo, and 
leprosy. Then diabetic ulcer, warts, Parkinson‟s. Hence the author decided to establish 
the safety of this formulation, which is needed in the current scientific world.    
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2.  AIM AND OBJECTIVES 
 
AIM 
 
To evaluate the safety profile (Acute and 28days Repeated dose oral 
toxicity study) of TAMBIRA PARPAM in Wistar albino rats. 
OBJECTIVES 
 To analyze the physico-chemical properties of Tambira parpam. 
 To evaluate Chemical and Spectroscopic analysis of Tambira    
 parpam. 
  To find out the safe dose of the Tambira parpam through toxicity    
 studies on Rodents as per OECD guidelines  423 & 407. 
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COPPER 
Copper: 
 Copper is a chemical element with symbol Cu   
 Atomic number 29.  
It is a soft, malleable, and ductile metal with very high thermal and electrical 
conductivity. 
[29]
 
A freshly exposed surface of pure copper has a reddish-orange color.  
      Copper is used as a conductor of heat and electricity, as a building material, and as 
a constituent of various metal alloys, such as sterling silver used 
in jewellery, cupronickel used to make marine hardware and coins, 
and constantan used in strain gauges and thermocouples for temperature 
measurement. 
 Copper is essential to all living organisms as a trace dietary mineral because it 
is a key constituent of the respiratory enzyme complex cytochrome c oxidase. 
In mollusks and crustaceans, Copper is a constituent of the blood 
pigment hemocyanin, replaced by the iron-complexed hemoglobin in fish and 
other vertebrates.  Copper is one of a few metallic elements with a natural colour 
other than grey or silver. Pure copper is orange-red and acquires a 
reddish tarnish when exposed to air.   
Chemical: 
Copper does not react with water, but it does slowly react with atmospheric 
oxygen to form a layer of brown-black copper oxide which, unlike the rust that forms 
on iron in moist air, protects the underlying metal from further corrosion. A green 
layer of verdigris (copper carbonate) can often be seen on old copper structures, such 
as the roofing of much older building. And the Statue of Liberty. 
Copper tarnishes when exposed to some sulphur compounds, with which it reacts to 
form various copper sulfides. 
Biochemical functions:
[30]
 
1. Copper is an essential constituent of several enzymes. These include cytochrome 
oxidase, catalase, tyrosinase, superoxide dismutase, monoamine oxidase, ascorbic 
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acid oxidase, ALA synthesis, phenol oxidase and uricase. Due to its presence in a 
wide variety of enzymes, Copper is involved in many metabolic reactions. 
2. Copper is necessary for the synthesis of hemoglobin (Cu is a constituent of ALA 
synthase). 
3. Lysyl oxidase (a copper-containing enzyme) is required for the conversion of 
certain lysine residues of collagen and elastin to allysine which is necessary for cross-
linking these structural proteins. 
4. Ceruloplasmin serves ass ferroxidase and is involved in the conversion of iron from 
Fe
2+ 
To Fe
3+  
in which form iron (transferrin) is transported in plasma.
 
5. Copper is necessary for the synthesis of melanin and phospholipids. 
6. Development of bone and nervous system (myelin) requires Cu. 
7. Certain copper-containing non-enzymatic proteins have been identified, although 
their functions are not clearly known. These include hemocuprein (storage form in the 
liver),cerebrocuprin (in the brain) and hemocuprein (in RBC). 
8. Hemocyanin, a copper-protein complex in invertebrates, functions like hemoglobin 
for O2 transport. 
Dietary requirements:
 [30]
 
 Adults                    -    2-3 mg/day 
 Infants and children -     0.5-2 mg/day 
Sources: 
Liver, kidney, meat, egg yolk, cereals, nuts and green leafy vegetables. Milk is a poor 
source. 
Dietary needs
 [31]
 
Copper is an essential trace element in plants and animals, but not all 
microorganisms. The human body contains copper at a level of about 1.4 to 2.1 mg 
per kg of body mass.  
Copper is absorbed in the gut and then transported to the liver bound 
to albumin. After processing in the liver, copper is distributed to other tissues in a 
second phase, which involves the protein ceruloplasmin, carrying the majority of 
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copper in blood. Ceruloplasmin also carries the copper that is excreted in milk and is 
particularly well-absorbed as a copper source.  
Copper in the body normally undergoes enterohepatic circulation (about 5 mg 
a day, vs. about 1 mg per day absorbed in the diet and excreted from the body), and 
the body is able to excrete some excess copper, if needed, via bile, which carries some 
copper out of the liver that is not then reabsorbed by the intestine.  
Plasma copper:
 [30]
 
The copper concentration of plasma is about 100-200µg/dl. Most of this (95%) 
is tightly bound to ceruloplasmin while a small fraction (5%) is loosely held to 
albumin. The normal concentration of serum ceruloplasmin is 25-50 mg/dl. It contains 
about 0.34% copper (6-8 atoms of Cu per molecule, half in Cu
2+
 state and the other 
half in Cu
+   
state). Ceruloplasmin is not a transport protein since this copper is not 
readily exchangeable with other molecules. The RBC contains erythrocuprein 
(superoxide dismutase).  
Effects of copper deficiency:
[32]
 
1. Although iron absorption is not disturbed the release of iron into the plasma is 
prevented due to the decreased synthesis of ceruloplasmin. As a result, 
hypoferremia occurs which leads to the depressed synthesis of heme 
developing anaemia in severe deficiency of copper. 
2. The experimental animals on a copper deficient diet lose weight and die. 
3. In copper deficient lambs, low cytochrome oxidase activity results in neonatal 
ataxia. 
4. Copper deficiency produces marked skeletal changes, osteoporosis, and 
spontaneous fractures. 
5. Elastin formulation is impaired in the deficiency of copper. Because a copper-
containing enzyme plays an important role in the connective tissue 
6. Metabolism, especially in the oxidation of lysine into aldehyde group which is 
necessary for cross-linkage of the polypeptide chains of elastin and collagen. 
7. Copper deficiency results in myocardial fibrosis in cows. It is suggested that 
reduction in cytochrome oxidase activity may lead to cardiac hypertrophy.  
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TOXICITY: 
Copper in the blood and blood stream exists in two forms: bound 
to ceruloplasmin (85–95%), and the rest "free", loosely bound to albumin and small 
molecules.  
Free copper normally reduces oxidative stress, as it is involved in the 
metabolic elimination of reactive oxygen species, such as with 
the superoxide radical through Cu-Zn dependent superoxide dismutase. Excessive free 
copper impairs zinc homeostasis, and vice versa, which in turn impairs antioxidant 
enzyme function, increasing oxidative stress. Chronically elevated levels of copper 
intake produce zinc deficiency. 
[33]
 
Nutritionally, there is a distinct difference between organic and inorganic 
copper, according to whether the copper ion is bound to an organic ligand. Organic 
copper, like that found in food, is a beneficial micronutrient needed for good 
health. Inorganic metallic copper, like that found in electrical wire, plumbing pipes, 
brass fittings, redox water filters, sheet metal, cooking utensils, jewelry, and pennies, 
is a neurotoxic heavy metal linked to physical and psychiatric symptoms on par with 
mercury and lead.  
Symptoms:  
Acute symptoms of copper poisoning  
 Vomiting,  
 Hematemesis (vomiting of blood),  
 Hypotension (low blood pressure),  
 Melena (black "tarry" feces), 
 Coma,  
 Jaundice (yellowish pigmentation of the skin),  
 Gastrointestinal distress.   
 Individuals with glucose-6-phosphate deficiency may be at increased 
risk of hematologic effects of copper. Hemolytic anemia resulting from 
the treatment of burns with copper compounds is infrequent.  
Chronic symptoms of copper poisoning 
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Chronic (long-term) effects of copper exposure can damage the liver and kidneys.  
Mammals have efficient mechanisms to regulate copper stores such that they 
are generally protected from excess dietary copper levels.   
The diagnostic difficulties arise from the fact that many of the substances that protect 
us from excess copper perform important functions in our neurological and endocrine 
systems. When they are used to bind copper in the plasma, to prevent it from being 
absorbed in the tissues, their own function may go unfulfilled. 
 Such symptoms often include 
 Mood swings,  
 Irritability,  
 Depression,  
 Fatigue, 
 Excitation,  
 Difficulty focusing,  
 Feeling out of control, etc.  
To further complicate diagnosis, some symptoms of excess copper are similar to those 
of a copper deficit. 
Toxicity in mammals includes a wide range of animals and effects such as  
 Liver cirrhosis,  
 Necrosis in kidneys and the brain,  
 Gastrointestinal distress,  
 Low blood pressure,  
 Fetal mortality.  
TREATMENT: 
In cases of suspected copper poisoning, penicillamine is the drug of choice, 
and dimercaprol, a heavy metal chelating agent, is often administered. Vinegar is not 
recommended to be given, as it assists in solubilizing insoluble copper salts. The 
inflammatory symptoms are to be treated on general principles, as are the nervous 
ones.
 [34] 
There is some evidence that alpha-lipoic acid (ALA) may work as a milder 
chelate of tissue-bound copper. Alpha lipoic acid is also being researched for 
chelating other heavy metals, such as mercury.  
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COOKWARE: 
Cookware in which copper is the main structural element (as opposed 
to copper clad, copper sandwiched or copper colored) is sometimes manufactured 
without a lining when intended to be used for any of a number of specific culinary 
tasks, such as preparing preserves or meringues.  
Excepting for acute or chronic conditions, exposure to copper in cooking is 
generally considered harmless. Following Paracelsus, dosage makes the poison; as 
this pertains to copper "a defense mechanism has apparently evolved as a 
consequence of which toxicity in man is very unusual."  
Acute exposure and attendant copper toxicity is possible when cooking or 
storing highly acidic foods in unlined copper vessels for extended periods, or by 
exposing foodstuffs to reactive copper salts (copper corrosion, or verdigris).  
Continuous, small exposures of acidic foods to copper may also result in 
toxicity in cases where either surface area interaction potentials are significant, pH is 
exceptionally low and concentrated (in the case of cooking with, for example, vinegar 
or wine), or both, and insufficient time elapses between exposures for normal 
homeostatic elimination of excess copper. 
BIRTH CONTROL: 
Estrogen birth control pills may increase the amount of copper in humans but 
be not shown to increase absorption. Copper Intrauterine devices (IUDs) have been 
questioned anecdotally, with people claiming copper toxicity, but there is currently no 
scientific evidence to substantiate this claim. Estrogen increases the absorption of 
copper, making women more likely to carry excess copper even when no birth 
controlis used. 
There are conditions in which an individual's copper metabolism is compromised to 
such an extent that birth control may cause an issue with copper accumulation.  
They include toxicity or just increased copper from other sources, as well as 
the increased copper level of the individual's mother via the placenta before birth. The 
two hormones commonly used in birth control, estrogen and progestin, protect from 
each other's complications, so a combination method may work best. At least when 
existing imbalances have been treated. 
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PATHOPHYSIOLOGY: 
Indian childhood cirrhosis
 
 
One manifestation of copper toxicity, cirrhosis of the liver in children (Indian 
childhood cirrhosis), has been linked to boiling milk in copper cookware. The Merck 
Manual states recent studies suggest that a genetic defect is associated with this 
particular cirrhosis.
[38]
 
Wilson's disease
 
 
An inherited condition called Wilson's disease causes the body to retain 
copper since it is not excreted by the liver into the bile. This disease, if untreated, can 
lead to brain and liver damage, and bis-choline tetrathiomolybdate is under 
investigation as a therapy for Wilson's disease. 
Alzheimer's disease
 [32]
 
Elevated free copper levels exist in Alzheimer's disease, which has been 
hypothesized to be linked to inorganic copper consumption. Copper and zinc are 
known to bind to amyloid beta proteins in Alzheimer's disease. This bound form is 
thought to mediate the production of reactive oxygen species in the brain. 
AQUATIC LIFE:  
Too much copper in water may damage marine and freshwater organisms such 
as fish and mollusks. Fish species vary in their sensitivity to copper, with the LD50 
for 96-h exposure to copper sulfate reported being in the order of 58 mg per liter for 
Tilapia and 70 mg per liter for catfish. The chronic effect of sublethal concentrations 
of copper on fish and other creatures is damage to gills, liver, kidneys and the nervous 
system. It also interferes with the sense of smell in fish, thus preventing them from 
choosing good mates or finding their way to mating areas.  
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4.  MATERIALS AND METHODS 
4.1 Selection of  the test drug: 
The test drug Tambira parpam  was selected  for the evaluation of toxicity studies in 
Wistar albino rats  
Ingredients of Tambira parpam: 
 Copper     
 Vettrilai charu     ( Piper betel  juice) 
 Munnaiilai charu (Premna corymbosa juice) 
 Ilai Kalli charu     (Euphorbia ligularia juice) 
 Vanniilai charu    (Prosopis spicigera juice) 
 Punnai  oil          (Calophyllum inophyllum oil)                  
 Kalapai kizhangu oil  (Gloriza suberba oil)          
  Procurement of the Raw drugs: 
 Thurusu (Copper sulphate) was procured from a reputed country shop in 
Chennai. The following herbal drugs such as vettriilai ( Piper betel) procured from 
Tambaram market,  Chennai. Then  Munnaiilai  (Premna corymbosa) Ilai kalli( 
Euphorbia ligularia) Vanniilai(Prosopis spicigera) collected from NIS Campus 
Chennai. 
Identification and Authentication of the raw drug:  
  The Herbal drugs were Identified and authenticated by Botanist, NIS 
Tambaram Sanatorium Chennai (Certificate No: NISMB2332016), The Metal drug 
was Identified and authenticated by pharmacologist in Siddha Central Research 
Institute   (SCRI) Arumbakkam Chennai. 
The purification process of  Copper: 
1.Copper powder 
2.Leaves juice of Red Cotton Tree (Gossypium arboretum) 
3.Goat’s urine 
4.Red cow’s urine  
5.Garden radish juice (Raphanus sativus) 
         Copper powder is soaked for 6 hours in the leaves juice of red cotton tree 
(Gossypium arboretum) and insolation for six days, adding fresh juice every day.                      
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         A seventh and eighth day, it is insolation without adding the juice until the 
moisture evaporates. This procedure is repeated with goat’s urine and red colored 
cow’s urine. Finally, it is soaked in the juice of radish (Raphanus sativus) and 
insolated for ten days by adding fresh juice every day. It is then isolated for two more 
days without adding juice and then place d in a fresh frying pan and roasted in husk 
flame until moisture evaporates.Then it is washed in clean water and then drug was 
placed in a cotton cloth for removing moisture content and insolated for obtaining 
purified copper. 
NOTE: Although it is stated that, it should be allowed to dry between each juice, if 
the watery contents does not absorb  and dried, it should be placed in the daylight and 
then processed in the next juice in the sunlight which is called “Sooriya pudam” by 
which the drug gets efficacy through the seven colour present in the sunlight. 
            Gossypium arboretum                              Raphanus sativus 
PREPARATION: 
35g   purified copper was placed in kalvam and it was ground with the 
following juices, Vettrilai charu for 16 days,  Munnaiilai charu for 12 days, Ilaikalli 
charu for 8 days,  Vanniilai charu for 4 days.  Then the grinding substance is made 
into a cake and dries it. After that, it was subjected to the pudam process. 
In this above process, only 4 part out of 6 is turned into parpam. Again the parpam 
was treated with punnai oil and Kalapai kizhangu oil by the churukku process. After 
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that whole portion became parpam, then it was placed in dew. The above prepared 
Tambira parpam was kept in an air tight glass container. 
Indication: 
 Earl kuruku veekam( hepatomegaly) 
 Nadukuvatham (Parkinson’s diseases) 
 Maarpu selanthe ( Breast tumor) 
 Yonni putru (vaginal cancer) 
 Gunman (peptic ulcer) 
 Pathavanmegam  (filariasis)  
 Naatpatta thalaivali (chronic headache) etc 
Adjuvant: Honey, ghee, milk, hot water, butter. 
Dose:  1.5 mg twice a day for 7 days  
                   Purified Copper                                                    Piper betel 
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ANALYTICAL STUDY OF TAMBIRA PARPAM: 
The Tambira parpam was subjected to following analytical studies like 
physicochemical analysis, Biochemical Analysis and Quantitative analysis by using 
sophisticated instruments.  
4.2 QUALITATIVE ANALYSIS 
The Tambira parpam was studied by physicochemical parameters. This study was 
done at The Tamil Nadu Dr. M.G.R. Medical University No.69, Anna Salai, Guindy, 
Chennai-600032, and Bureau Veritas Consumer Products Services (India) Pvt.Limited 
Chennai. 
A. PHYSICO-CHEMICAL PROPERTIES    
1. Moisture Content:  
An accurately weighed 3g of Tambira parpam  was taken in a tarred glass bottle. 
The crude drug was heated at 105
0
C in an oven till a constant weight. Percentage 
moisture content of the sample was calculated with reference to the shade dried 
material.
[35] 
 
Calculation: 
                                                                     Loss in weight of test drug   
  Percentage of loss on drying at 105ºC   =   ------------------------------------- x 100 
                                                                     Weight of test drug taken  
 
2. Determination of total ash: 
Weighed accurately 2g of Tambira parpam was added in the crucible at a 
temperature 500-600
0
C in a muffle furnace till carbon- free ash was obtained. It was 
calculated with reference to the air- dried drug. 
[35]
 
Calculation:   
                                                                      Weight of the ash   
                              Percentage of total ash   =   --------------------------------- x 100 
                                                   Weight of test drug taken 
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3. Determination of acid insoluble ash: 
Ash above obtained, was boiled for 5min with 25ml of 1M Hydrochloric acid and 
filtered using an ashless filter paper. Insoluble matter retained on filter paper was 
washed with hot water and filter paper was burnt to a constant weight in a muffler 
furnace. The percentage of acid insoluble as was calculated with reference to the air-
dried powdered drug.
 [35]
 
Calculation: 
                                                Weight of the acid-insoluble residue   
Percentage of acid-insoluble ash   =   -------------------------------------------- x 100 
                                              Weight of test drug taken 
3. Determination of water soluble ash: 
Total ash 1g was boiled for 5min with 25ml water and insoluble matter collected 
on an ashless filter paper was washed with hot water and ignited for 15min at a 
temperature not exceeding 450
0
C in a muffle furnace. The difference in weight of ash 
and weight of water.
 [35]
 
4. Determination of water soluble Extractive: 
1gm of air dried drug, coarsely powered Tambira parpam was macerated with 
100ml of distilled water in a closed flask for twenty-four hours shaking frequently. 
The solution was filtrated and 25 ml of filtrate was evaporated in a tarred flat bottom 
shallow dish, further dried at 100
0
 C and weighted. The percentage of water soluble 
extractive was calculated with reference to the air- dried drugs.
 [35]
   
Calculation: 
                                                                   Weight of the extract             100 
   Percentage of water soluble extract   =   -------------------------------- x --------- x 100  
                                            Weight of sample taken          25 
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6. Determination of alcohol soluble extractive: 
1 gm. of air dried drugs, coarsely powdered Tambira parpam was macerated 
with 100 ml. alcohol in closed flask for 24 hrs. With frequent shaking. It was filtered 
rapidly taking precaution against loss of alcohol. 25ml of the filtrate was then 
evaporated in a tarred flat bottom shallow dish, dried at 100
0
C and weighted. The 
percentage of alcohol soluble extractive was calculated with reference to air dried 
drug.
 [35] 
 
Calculation: 
                                                                Weight of the extract     100 
 Percentage of alcohol soluble extract   = -------------------------- x ------------- x 100  
                                         Weight of sample taken     25 
5. Determination of pH   
The pH, of the Tambira parpam was estimated as per the method prescribed in 
the Indian standard (IS) APHA
 [36]
 4500 H+A, B. The procedure was done at Bureau 
Veritas; Chennai 32.One gram of the test drug was taken into a 100ml graduated 
cylinder containing about 50 ml of water. The cylinder was  shaken vigorously for 
two minutes and the suspension was allowed to settle for hour at 25ºC  to 27ºC, then 
25 ml of the clear aqueous solution was transferred into a 50 ml beaker and tested for 
pH using digital pH meter 
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B. CHEMICAL EVALUATION 
  Experimental procedure:  
          5 g of Tambira parpam was taken in a 250 ml of clean beaker and 50ml of 
distilled water was added to it. Then it was boiled well for about 10 min. Then it is 
allowed to cool and filtered into a 100 ml volumetric flask and made up to 100 ml 
with distilled water. This preparation is used for the qualitative analysis of acidic/ 
basic radicals and biochemical constituents in it. The biochemical analysis of Tambira 
parpam was done at Biochemistry Lab, National Institute of Siddha, Chennai-47. 
A preliminary test for Copper, Sodium, Silicate and Carbonate: 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Appearance of sample Dark grey in 
colour  
 
2. Test for Silicate: 
a. A little (500mg) of the sample is 
shaken well with distilled water. 
b. A little(500mg) of the sample is 
shaken well with con. HCl/Con. H2So4 
 
Sparingly not 
soluble 
Absence of 
Silicate 
3. Action of Heat: 
   A small amount (500mg) of the 
sample is taken in a dry test tube and 
heated gently at first and then strong. 
White fumes    
evolved 
 
Presence of 
Carbonate 
 
4. Flame Test: 
  A small amount (500mg) of the 
sample is made into a paste with con. 
HCl in a watch glass and introduced 
into a non-luminous part of the 
Bunsen flame. 
Bluish green flame 
appeared 
Presence of 
Copper 
5. Ash Test: A filter paper is soaked in a 
mixture of sample and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
No 
Yellow colour 
flame appeared 
Absence of 
Sodium 
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Test For Acid Radicals 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Test For Sulphate: 
2ml of the above-prepared extract was 
taken in a test tube and 2ml of 4% dil. 
ammonium oxalate solution was added. 
Presence of 
Cloudy 
appearance 
 
Sulphate  
present  
2. Test For Chloride:  
 2ml of the above-prepared extracts was 
added with 2ml of dil-HNO3 until the 
effervescence ceases off. Then 2 ml of 
silver nitrate solution was added. 
Presence of 
Cloudy 
appearance 
Chloride 
present 
 
3. Test For Phosphate: 
 2ml of the extract was treated with 2ml of 
con.HNo3 and 2ml of dil. ammonium 
molybdate solution.   
 
Absence of 
Yellow precipitate 
 
 
Phosphate 
absent 
4.  Test For Carbonate: 
    2ml of the extract was treated with 2ml 
dil. magnesium sulfate solution 
Presence of 
Cloudy 
appearance 
 Carbonate 
Present 
 
 
5. Test For Nitrate: 
  1gm of the substance was heated with 
copper turning and concentrated H2SO4 
and viewed the test tube vertically down. 
Brown gas was 
not evolved 
Nitrate absent 
6. Test For Sulphide: 
  1gm of the substance was treated with 
2ml of the con. HCL 
Rotten Egg 
Smelling gas was 
not evolved 
Sulphide absent 
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7. Test For Fluoride & Oxalate: 
  2ml of the extract was added with 2ml of 
dil. Acetic acid and 2ml dil. calcium 
chloride solution and heated. 
Presence of 
Cloudy 
appearance 
fluoride and 
oxalate Present 
8. Test For Nitrite: 
  3drops of the extract was placed on a 
filter paper, on that-2 drops of dil. acetic 
acid and 2 drops of dil. Benzidine solution 
was placed. 
Characteristic 
changes not 
appeared 
Nitrite absent 
                                                    
Test For Basic Radicals 
1. Test For Lead: 
        2ml of the extract was added with 
2ml of dil. potassium iodine solution. 
 
 
Yellow 
Precipitate was 
not obtained. 
 
Lead         
absent 
2. Test For Copper: 
  One pinch (50mg) of substance was 
made into a paste with con. HCl in a watch 
glass and introduced into the non-
luminous part of the flame. 
The blue colour 
precipitate 
formed. 
 
Copper                       
Present 
 
 
3. Test For Aluminium: 
  In the 2ml of extract dil. sodium 
hydroxide was added in 5 drops to excess. 
Yellow colour 
was not formed 
Aluminium 
absent 
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4. Test For Iron: 
a. To the 2ml of extract add 2ml of dil. 
ammonium solution 
b.  To the 2ml of extract, 2ml  thiocyanate 
solution and 2ml  of con HNo3 is added 
 
Absence of brown 
precipitate 
Red colour  
formed 
 
Iron         
Present 
 
5. Test For Zinc:  
      In 2ml of the extract dil. sodium 
hydroxide solution was added in 5 drops 
to excess and dil. Ammonium chloride 
was added.  
White precipitate 
was not formed 
Zinc          
absent 
6. Test For Calcium:  
      2ml of the extract was added with 2ml 
of 4% dil. ammonium oxalate solution  
Cloudy 
appearance was  
formed 
Calcium  
present 
7. Test For Magnesium:  
In 2ml of extract dil. sodium hydroxide 
solution was added in drops to excess. 
 
white precipitate 
not formed 
 
Magnesium 
absent 
8. Test For Ammonium: 
  In 2ml of extract 1 ml of Nessler's 
reagent and excess of dil. sodium 
hydroxide solution was added. 
 
Brown colour not 
formed 
 
Ammonium 
absent 
 
9.   Test For Potassium: 
 A pinch (25mg) of substance was treated 
with 2ml of dil. sodium nitrite solution and 
then treated with 2ml of dil. cobalt nitrate 
in 30% dil. glacial acetic acid. 
 Yellowish 
precipitate  
formed 
 
Potassium 
Present 
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10. Test For Sodium: 
    2 pinches (50mg) of the substance was 
made into a paste by using HCl and 
introduced into the blue flame of Bunsen 
burner. 
 
Yellow colour 
flame not 
appeared 
 
Sodium      
absent 
11. Test For Mercury:  
 2ml of the extract was treated with 2ml of 
dil. sodium hydroxide solution.  
 
Yellow precipitate 
not formed 
 
Mercury   
absent 
12. Test For Arsenic:  
   2ml of the extract was treated with 2ml 
of dil. sodium hydroxide solution. 
 
Brownish red 
precipitate not 
formed 
 
Arsenic     
absent 
                                                       Other constituents 
1.  Test For Starch: 
 2ml of extract was treated with weak dil. 
iodine solution  
Blue colour 
developed 
Starch             
present 
2.  Test For Reducing Sugar:  
 
5ml of Benedict's qualitative solution was 
taken in a test tube and allowed to boil for 
2 minutes and added 8 to 10 drops of the 
extract and again boil it for 2 minutes.  
 
The was no 
specific change in 
colour 
 
Reducing sugar 
absent 
3.  Test For The Alkaloids: 
a) 2ml of the extract is treated with 
2ml of dil. Potassium iodide 
solution.     
b) 2ml of the extract is treated with 
2ml of dil. picric acid. 
Reddish brown 
precipitation not 
formed 
Yellow 
precipitation 
formed 
 
Alkaloid 
Present 
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4.  Test For Tannic Acid:  
  2ml of the extract was treated with 2ml of 
dil. ferric chloride solution 
 
Black precipitate 
not formed 
 
Tannic acid 
absent 
5.  Test For Unsaturated Compound: 
  In the 2ml of extract 2ml of dil. 
Potassium permanganate solution was 
added.  
Potassium 
permanganate not 
decolorized 
 
unsaturated 
compounds 
Absent 
6.  Test For Amino Acid: 
    2 drops of the extract were placed on a 
filter paper and dried well, and then 20ml 
of Biuret reagent was added to it. 
 
Violet colour not  
developed 
 
Amino acids 
absent 
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4.3 QUANTITATIVE ANALYSIS 
Tambira parpam was analyzed in the presence of heavy metals by using ATOMIC 
ABSORPTION SPECTROMETER (AAS).This study was done at Asthagiri Herbal 
Research Foundation, 162-A, Perugudi Industrial Estate, Perungudi, Chennai-96 
1. ATOMIC ABSORPTION SPECTROMETER (AAS) 
ESTIMATION OF HEAVY METALS: 
The procedure recommended for analysis of Heavy metals like Lead, Cadmium, 
Arsenic, and Mercury in WHO, 1998 and AOAC, 2005. and copper was analysed by 
Standard method. 
INSTRUMENT DETAILS: 
UV-Vis spectrometer AA240 series, UV 8500 Absorption Spectrometer(AAS) was 
used for the analysis. The operating parameters: 
 Instrument technique: UV Method 
Wavelength (Lead)                                     : 500 nm 
Wavelength (Cadmium)                             : 228.8 nm 
Wavelength (Mercury)                               : 253.7 nm 
Wavelength (Arsenic)                                : 193.7 nm 
Wavelength (Copper)                                 : 324.8 nm 
The hollow cathode lamp for Hg, As, Pb, Cd, and Cu were used as a light source to 
provide wavelength for the elements to be determined. 
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                                          2.  Thermogravimetric analysis 
 
Thermogravimetric analysis or thermal gravimetric analysis (TGA) is a 
method of thermal analysis in which changes in physical and chemical properties of 
materials are measured as a function of increasing temperature (with constant heating 
rate), or as a function of time (with constant temperature and or constant mass loss).   
TGA can provide information about physical phenomena, such as second-
order phase transitions, including vaporization, sublimation, absorption, 
and desorption. Likewise, TGA can provide information about chemical phenomena 
including chemisorptions, desolvation (especially dehydration), decomposition, and 
solid-gas reactions (e.g., oxidation or reduction).
[37] 
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 TGA is commonly used to determine selected characteristics of materials that 
exhibit either mass loss or gain due to decomposition, oxidation, or loss 
of volatiles (such as moisture). 
 Common applications of TGA :
[38]
 
 (1) materials characterization through analysis of characteristic decomposition 
patterns. 
(2) studies of degradation mechanisms and reaction kinetics, (3) determination 
of organic content in a sample. 
 (4) determination of inorganic (e.g. ash) content in a sample, which may be 
useful for corroborating predicted material structures or simply used as a chemical 
analysis. It is an especially useful technique for the study of polymeric materials, 
including thermoplastics, thermosets, elastomers, composites,  
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3.Fourier transform infrared spectroscopy (FTIR) 
                 
Fourier transform infrared spectroscopy (FTIR) is a technique which is used to 
obtain an infrared spectrum of absorption or emission of a solid, liquid or gas. An 
FTIR spectrometer simultaneously collects high spectral resolution data over a wide 
spectral range. This confers a significant advantage over a dispersive spectrometer 
which measures intensity over a narrow range of wavelengths at a time. 
The term Fourier transform infrared spectroscopy originates from the fact that 
a Fourier transform (a mathematical process) is required to convert the raw data into 
the actual spectrum. For other uses of this kind of technique, see Fourier transform 
spectroscopy. 
The standard method to prepare a solid sample for FTIR spectrometer is to use KBr. 
About 2 mg of Tambira parpam and 200 mg KBr are dried and ground. The particle 
size should be unified and less than two micrometers. Then, the mixture is squeezed 
to form transparent disc which can be measured directly. For liquids with a high 
boiling point or viscous solutions, it can be added in between two NACL pellets. Then 
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the sample is fixed in the cell by skews and measured. For a volatile liquid sample,  it 
is dissolved in CS2 or CCL4 to form 10% solution.  Then the solutions are injected 
into a liquid cell for measurement. Gas sample needs to be measured in a gas cell with 
two KBr windows on each side. That gas cell should first be vacuumed. Then the 
sample can be introduced into the gas cell for measurement. 
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4.X-ray Powder Diffraction (XRD) 
 
 
 
 
 
 
 
 
 
 
                   
 
X-ray powder diffraction (XRD) is a rapid analytical technique primarily used for 
phase identification of a crystalline material and can provide information on unit cell 
dimensions. The analysed material is finely ground, homogenized, and average bulk 
composition is determined. 
Crystalline substances act as three-dimensional diffraction gratings for X-ray 
wavelengths similar to the spacing of planes in a crystal lattice. X-ray diffraction is 
now a common technique for the study of crystal structures and atomic spacing.X-ray 
diffraction is based on constructive interference of monochromatic X-rays and a 
crystalline sample. These X-rays are generated by a cathode ray tube, filtered to 
produce monochromatic radiation, collimated to concentrate, and directed toward the 
sample. The interaction of the incident rays with the sample produces constructive 
interference (and a diffracted ray) when conditions satisfy Bragg's Law (nλ=2d sin θ). 
This law relates the wavelength of electromagnetic radiation to the diffraction angle 
and the lattice spacing in a crystalline sample.  
QUANTITATIVE ANALYSIS 
 
Preclinical Safety Evaluation  Of Tambira Parapm Page 50 
 
These diffracted X-rays are then detected, processed and counted. By scanning the 
sample through a range of 2θangles, all possible diffraction directions of the lattice 
should be attained due to the random orientation of the powdered material. 
Conversion of the diffraction peaks to d-spacing allows identification of the mineral 
because each mineral has a set of unique d-spacings. Typically, this is achieved by 
comparison of d-spacing with standard reference patterns. 
All diffraction methods are based on the generation of X-rays in an X-ray tube. These 
X-rays are directed at the sample, and the diffracted rays are collected. A key 
component of all diffraction is the angle between the incident and diffracted rays. 
Powder and single crystal diffraction vary in instrumentation beyond this. 
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5.SCANNED ELECTRON MICROSCOPY(SEM) 
                       
 
 
 
 
 
 
 
A SEM  is essentially a high magnification microscope, which uses a focused scanned 
electron beam to produce images of the sample, both top-down and, with the 
necessary sample preparation, crosses sections. The primary electron beam interacts 
with the sample in  a number of key ways:- 
 A primary electron generates low energy secondary electron, which tends to 
emphasize the topographic nature of the specimen. 
 A primary electron can be backscattered which produces images with a high 
degree of atomic number (Z) contrast. 
 Ionized atoms can relax by electron shell-to-shell transitions, which lead to 
either X-ray emission or Auger electron ejection. The X-ray emitted are 
characteristic of the elements in the top few µm of the sample. 
The SEM is carried out by using FEI-Quanta FEG 200-High Resolution  Instrument. 
Resolution: 1.2 nm gold particle separation on a carbon substrate 
Magnification: From a min of 12x to greater than 1,00,000X 
Application:  To evaluate grain size, particle size distributions, material homogeneity 
and intermetallic distributions.  
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4.4 TOXICITY STUDIES OF TAMBIRA PARPAM 
To evaluate the safety profile of Tambira parpam acute and subacute toxicity study 
carried out as followed 
Principles of laboratory animal care were followed and the Institutional Animal 
Ethical Committee approved the use of animals and the study design. Institutional 
Animal Ethical Committee approval number:  (IAEC). (NIS/IAEC/I/2016/09 dated 
12.2.2016) for acute toxicity study and (NIS/IAEC/II/2016/06 dated 28.3.2016) for 
repeated dose 28-day oral toxicity study.   
1. ACUTE TOXICITY STUDY OF TAMBIRA PARPAM[7]  
Experimental Animals: 
Species              : Wistar Albino Rats 
Sex      :  Female 
Age/weight     : 6 weeks/140-160g b.wt 
Acclimatization Period  : 7 days prior to dosing 
Housing    :  Polypropylene cages with bedding with   
                                                                 Husk 
Husbandry    : 12-h light/12-h dark cycle/ 
                                                                Room temperature 22°C ± 3°C and 
                                                                Relative humidity 30–70% 
Feed and Water   :   Rodent pelleted feed 
                                                                 RO purified water ad libitum 
Identification   :  Animals will be kept in 
                                                                  Polypropylene cages and 
                                                                 Numbered 
 
Experimentation Details of Acute Toxicity Study: 
Groups/Treatment regimen  : Grouped by randomisation 
Test Guideline    : OECD-423 
Length of exposure to test substance : Once single dose 
No of Animals    : 3 Female/ group 
Control group    : Vehicle (honey) 
Test groups    : Tambira parpam 5,50,300,2000 mg/kg.         
                                                                           b.wt  
 
 The Female Albino Rats of weighing 150-200g were obtained from authorized 
animal breeders of the animal laboratory in TANUVAS, Madhavaram, and Chennai 
and stocked in the animal house at National Institute of Siddha, Chennai.  Animals 
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were housed in a cage at 22°C ±3°C and relative humidity 30–70% and have free 
access to standard rat pellet diet (Sai Meera Foods Pvt. Ltd., Bangalore). The animals 
were treated with Tambira parpam by oral route for one day and monitored for 
behavioral parameters for the first 4 hours (1/2 hr, 1hr,2 hr, 3 hr,4 hr) after drug 
administration. Body weight of the animal will be monitored at weekly intervals. The 
animals that the die within this period will be subjected to necropsy. Remaining 
animals will be weighed and sacrificed under the injection of Pentothal Sodium on the 
15
th 
day of the Study period. The toxicological effect was assessed on the basis of 
mortality. 
Preparation of Test Drug Doses: 
Groups No. of Rat 
Group I:  Vehicle control (honey) 3Female 
Group II : test  drug– 5mg/kg b.wt 3 Female 
Group III: test drug – 50 mg/kg b.wt 3 Female 
Group IV: test drug – 300 mg/kg b.wt 3 Female 
Group V: test drug – 2000 mg/kg b.wt 3 Female 
 
Route of administration 
Oral route was selected because it is the normal route of clinical 
administration. 
Administration of Dose 
The animals were fasted (only food was withheld) for 12hrs and weighed prior to 
dosing. Three animals were used for each step. A single dose of the solution (5, 50, 
300,2000mg/kg) was consecutively administered by oral gavage using intubation 
cannula. The food was withheld for another 4hrs after dosing and administration of 
the drug. As per the guideline, the starting dose level was taken as 5mg/kg body 
weight. 
Observations: 
 Observations were made and recorded systematically and continuously 
observed after the substance administration as per the guidelines.  
 ½ hour, 1 hour, 2 hours, 4 hours and up to 24 hours observation 
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 All rats were observed twice daily for 14 days 
 Body weight  were Calculated weekly once  
 Feed & water intake  were Calculated daily 
Cage side observation  
The animals were monitored for behavioral parameters like Alertness, 
Aggressiveness, piloerection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis 
Analgesia, Lacrimation, Exophthalmos, Diarrhea, Writhing,  Respiration, Mortality 
Gross necropsy: 
At the end of the 14 
th
 day, all the animals were sacrificed by using the injection of 
Pentothal sodium Gross necropsy includes examinations of the external surface of the 
body, all orifices, cranial, thoracic and abdominal cavities and their contents. Brain, 
eye, lungs, heart, spleen, liver, kidneys, adrenals, uterus, of all animals. 
2. REPEATED DOSE 28-DAY ORAL TOXICITY STUDY OF TAMBIRA 
PARPAM
[8] 
Experimental Animals: 
Species               : Wistar Albino Rats 
Sex      : Male and Female 
Age/weight  at start of test  : 6 weeks/140-160g b.wt 
Acclimatization Period  : 7 days prior to dosing 
Housing    :  Polypropylene cages with  bedding with   
                                                                 Husk  
Husbandry    : 12-h light/12-h dark cycle/ 
                                                                Room temperature 22°C ± 3°C  and 
                                                                Relative humidity 30–70% 
Feed and Water   :  Rodent pelleted feed 
                                                               RO purified water ad libitum 
Identification   : Animals will be kept in 
                                                               Polypropylene cages and 
                                                               Numbered 
 
Experimentation Details of Repeated dose 28 days Toxicity Study: 
Groups/Treatment regimen  : Grouped by randomisation 
Test Guideline    : OECD-407 
Length of exposure to test substance : 28 days 
No of Animals    : 3 Female+3 Male / group 
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Control group    : Vehicle (honey) 
Test groups    : Tambira parpam (Low dose, Mid dose,               
                                                                        High dose & Satellite group      
           The 30 Wistar albino rats of both sexes selected randomly. The animals were 
divided into five groups. Each group consists of 6 animals. The first group treated as 
vehicle control and second, third, four, fifth group were treated with Tambira parpam 
Low-dose (100 mg), Mid dose (200 mg), High-dose (400 mg) and satellite group (400 
mg) respectively. The satellite group was included to determine delayed occurrence or 
recovery from toxic effects. The control animals were administered with honey as a 
vehicle.The other animals treated with  Tambira parpam which was m i x ed  w i th  
honey at the dose levels  of L o w  d o s e 100mg/ kg b.wt,  Mid dose200 mg/kg 
b.wt and  High dose 400 mg/kg b.wt and Satellite group or to retrieval group 
400mg/kg b.wt. For 28 days. The administration was given by oral, once daily for 28 
consecutive days. The animals were observed the behavioural parameters for the 
study period. Body weight of the animal was being monitored at weekly intervals. 
Food & water intake were Calculated daily. All the animals were sacrificed at the end 
of the study (29 days) by using the injection of Pentothal Sodium and satellite group 
was sacrificed after 14 days of drug withdrawal by using an injection of Pentothal 
sodium. Blood was collected from the anesthetized animals from the Abdominal aorta 
for the following investigations like Haematology, Biochemical analysis. Gross 
pathological changes were monitored the animals and then the organs were studied by 
histopathological examination. 
 
The doses (Low, Mid, High dose) were fixed from the result from the acute toxicity 
study 
Groups No. of Rats 
Group I:  Vehicle control (honey) 6(3M+ 3F) 
GroupII:Test drug (Tambira parpam)- low dose (100mg/Kg b.wt) 6(3M + 3F) 
GroupIII: Test drug(Tambira parpam) - Mid dose (200mg/Kg b.wt) 6(3M +3F) 
GroupIV:Ttest drug(Tambira parpam) High dose ( 400mg/Kg b.wt) 6(3M +3F) 
GroupV:Test drug(Tambira parpam)Satellite group(400mg/Kg b.wt) 6(3M+3F) 
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Observations: 
Experimental animals were kept under observation throughout the course of 
study for the following 
 All rats were observed twice daily for 28 days 
 Body weight  were Calculated weekly once  
 Feed & water intake  were Calculated daily 
Cage side observation   
The animals were monitored for behavioral parameters like, Alertness, 
Aggressiveness, piloerection, Grooming, Gripping, Touch Response, Motor Activity, 
Tremors, Convulsions, Muscle Spasm, Catatonia, Muscle relaxant, Hypnosis 
Analgesia, Lacrimation, Exophthalmos, Diarrhea, Writhing,  Respiration, Mortality. 
 
Laboratory Investigations: 
On the 29
th 
day, the animals were fasted overnight, then anesthetized to collect 
blood samples from the abdominal aorta in two tubes:  one with  EDTA  for 
hematological parameters, another one without any anticoagulant and was 
centrifuged at 4000 rpm at 4°C for 10 minutes to obtain the serum for biochemical 
parameters. 
Hematological Investigations: 
Blood samples of control and experimental rats were analyzed for 
haemoglobin (Hb), total red blood corpuscles  (RBC),  white blood corpuscles  
(WBC) count, Platelet, Mean corpuscular volume (MCV), Mean corpuscular 
hemoglobin (MCH), were calculated by auto analyzer. 
Biochemical Investigations: 
Serum samples of control and experimental animals were analyzed for, 
Bilirubin, BUN, Creatinine, Triglyceride, Total Cholesterol, HDL, LDL, VLDL, 
using standard methods. Activities of glutamate oxaloacetate transaminase/ 
TOXICITY STUDIES 
 
Preclinical Safety Evaluation  Of Tambira Parapm Page 57 
 
Aspartate aminotransferase (GOT/AST), glutamate pyruvate transaminase/ Alanine 
aminotransferase (GPT/ALT) were estimated as per the colorimetric procedure.  
Necropsy: 
 All the animals were sacrificed on the 29
th 
day and satellite group were sacrificed on 
after 14 days. Gross necropsy includes examinations of the external surface of the 
body, all orifices, cranial, thoracic and abdominal cavities and their contents. Brain, 
eye, lungs, heart, spleen, liver, kidneys, adrenals, sex organs, of all animals were 
recorded. 
Histopathology: 
The organs included liver, kidneys, spleen, brain, heart, lungs and stomach 
of the animals were preserved, and they were subjected to histopathological 
examination. 
Histopathological investigation of the vital organs was done. The organ pieces (3-
5µm thick) of all the animals (low, mid, high) a n d  satellite group w e r e  
preserved and fixed in 10% formalin for 24 hrs. Samples were dehydrated in an auto 
technic and then cleared in benzene to remove absolute alcohol.  Embedding was 
done by passing the cleared samples through three cups containing molten paraffin at 
50
oC and then in a cubical block of paraffin made by the “L” molds. It was followed 
by microtome and the slides were Prepared then stained with Haematoxylin-eosin. 
Statistical analysis: 
Findings   such   as  body weight   changes,   food consumption,   water   
intake, hematology and biochemical analysis were subjected to One-way ANOVA 
Dunnet’s test using a computer software program  followed by D Graph Pad Instat-3  
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                                                              RESULT 
Standardization of Parpam in Siddha Aspect 
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5.1 QUALITATIVE ANALYSI S 
PHYSICO-CHEMICAL ANALYSIS 
Table-1: Colour, nature, and pH of Tambira parpam 
 
From Table 1, The Organoleptic characters shows that Tambira parpam is dark grey 
in colour and odourless powder form of drug with pH of 8.97. It is soluble in honey, 
milk and insoluble in water, acetone and ether. 
 
 
 
 
 
 
 
 
 
 
 
 
S.no Parameters Results Method of Testing 
 
1. Colour Dark grey By visual 
 
2. Odour Odourless Olfactory examination 
 
 
3. Solubility  Soluble in 
honey&milk 
 Insoluble in 
water,acetone& 
ether 
Qualitative 
 
 
 
 
4. Nature Powder By visual 
 
5. pH 8.97% APHA 4500H+A,B 
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Table-2: Physico-chemical properties of Tambira parpam 
S.no Parameters Percentage 
1 Moisture content 1.9160% 
2 Total ash value 96.36% 
 
3 Acid insoluble ash 22.84% 
4 Water soluble ash 9.88% 
5 Water soluble extraction 11.56% 
6 Alcohol soluble extraction 1.84% 
 
From Table 2, The Physico-chemical analysis of Tambira parpam  explained 
in the parameters such as Moisture content, Total ash value, Acid insoluble ash, Water 
soluble ash, Water soluble extraction, Alcohol soluble extraction and pH are within 
the normal limits according to PLIM guidelines. 
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Table-3: Test for Basic radicals 
S.no Procedures Tambira parpam 
 
1. Test for Ammonium  
- 
2. Test for Sodium - 
 
3. Test for Magnesium - 
 
4. Test for Aluminium - 
 
5. Test for Potassium + 
 
6. Test for Calcium + 
 
7. Test for Ferrous iron  
+ 
8. Test for Copper  
+ 
9. Test for Zinc  
- 
10. Test for Arsenic - 
 
11. Test for Mercury - 
 
12. Test for Lead - 
 
 
From Table 3, The Biochemical analysis for basic radical reveals that 
Tambira parpam contains Potassium, Calcium, Iron, and Copper. 
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Table-4: Test for Acidic radicals 
S.no Procedures Tambira parpam 
 
1. Test for Sulphate  
+ 
2. Test for Chloride + 
 
3. Test for Phosphate _ 
 
4. Test for 
Flouride&Oxalate 
 
+. 
5. Test for Nitrate _ 
 
 
Table-5: Test for Acidic radicals 
S.no Procedures Tambira parpam 
 
1. Test for Starch                + 
 
2. Test for Reducing sugar                _ 
 
3. Test for Alkaloids                _ 
 
4. Test for Amino Acids _ 
 
5. Test for Tannic acids _ 
 
6. Test for type of 
compounds 
Oxyquinoline, 
epinephrine, 
Pyro catechol 
 
From Table 4&5, The Biochemical analysis for acid radicals reveals that Tambira 
parpam contains Sulphate, Chloride, Fluoride, Oxalate, Starch, Oxyquinoline, 
epinephrine and Pyro catechol. 
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5.2 QUANTITATIVE ANALYSIS 
A. ATOMIC ABSORPTION SPECTROSCOPY 
Heavy metals content of Tambira parpam was analyzed by AAS this results 
Tabulated in Table 6.  
Table-6: Analysis of Heavy Metals 
S.no Name of the Element Results Permissible 
limit 
 
1. Lead BDL 10 ppm(WHO) 
 
2. Cadmium BDL 0.3 ppm(WHO) 
 
3. Mercury BDL 1ppm(WHO) 
 
4. Arsenic BDL 3ppm(WHO) 
 
5. Copper 11.139 - 
 
 
BDL – Below Detection Limit 
From Table 6, The Atomic Absorption Spectroscopy result shows that the 
heavy metals present in Tambira parpam were found to be within normal limits as per 
WHO, at the same time the Copper content of test drug is 11.139 ppm. 
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B.Thermogravimetry Analysis of Tambira parpam 
                                                          Graph 1                      
 
                                         Thermogravimetry Analysis 
Thermogravimetric analysis of Tambira Parpam carried out at the maximum of 
1000
0
C.  The main objective of the study is to evaluate the decomposition and 
stability limit of the prepared formulation Tambira parpam. Prepared formulation 
Tambira parpam seems to be stable at the temperature varying from 50 ºC to 800 ºC 
with no variation in the residual weight. The point of decomposition begins when the 
temperature increases beyond 800 ºC. Sharp deletion curve observed from 800 ºC to 
825 ºC and at this point suggested crystal transformation may be observed. Predicted 
denaturation may be due to atomic change at oxygen atom present within the sample. 
Weight of the final residual matter was observed as 3.307 mg with 75.14% of 
residual volume. The remaing portion (approximately 25%) contains organic 
compounds also. 
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SR No 17-02-X-2459-070317.pk
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C. FT-IR Analysis of Tambira  Parpam 
Graph 2 
 
                                           FTIR analysis of Tambira parpam 
Infrared absorption pattern of CuO stretching was observed in the region of 523.16 
cm−1 to 691.5  cm−1.Sharp absorption peak observed in the region of 590.87 cm−1 
indicates the IR spectral pattern of CuO. Absorbance peak at 1107.93 cm−1 
corresponds to CuO vibration due to metal cation. Broad absorption peak at 3367.73 
cm−1 corresponds to O-H stretching which is bonded. Wide absorption peaks at 1645 
cm−1 may be due to presence of primary amino group and also due to vibrational 
intensity of C=C group,1404 cm−1 corresponds to CH2 Bending, 1463 cm−1 
corresponds to CH2 deformation. 
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D. X-ray diffraction pattern of Tambira parpam 
Graph 4 
 
 
 
 
 
 
 
 
 
 
 
XRD Analysis 
The X-ray diffraction pattern of the prepared formulation Tambira  Parpam reveals 
the presence of a major peak with 2- Theta value of 38.719 which exactly matches to 
the ICDD (International Centre for Diffraction Data) 80- 1916. ICDD801916 
corresponds to the crystalline pattern of copper oxide (CuO).Hence the reference 
matching material was confirmed as copper oxide (CuO). Major peaks observed in  
Tambira parpam  with  2-theta  values of  35.49  and their corresponding intensities 
were 3492.The major peak observed in the reference matching material was 38.68 
with the intensity value of 999.The  XRD  pattern of the test  (Tambira  Parpam)  
exactly matches with the reference material CuO, which justifies the presence of 
stable and purified CuO in the formulation.  
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E. SCANNED ELECTRON MICROSCOPY 
Determination of Particle size of Tambira parpam 
Figure-1:  SEM Image of Tambira parpam 
 
 
 
 
 
 
 
 
 
                                   SEM image of Tambira  Parpam 
Figure 2: 
 
 
 
 
 
 
 
                                 SEM image of Tambira  Parpam 
Results:  
Particle Size : 10.17nm to 22.9 µm 
Shape : Spherical 
Surface : Smooth 
Distribution : Evenly distribute 
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ACUTE TOXICITY STUDY 
Table7.   Behavioural Signs of Acute Toxicity Study of Tambira parpam
[7]
 
No Dose 
Mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + + + - - - - - - - - - - - - + - 
 
2. 5 + - - + + + - - - - - - - - - - - - + - 
 
3. 50 + - - + + + - - - - - - - - - - - - + - 
 
4. 300 + - - + + + - - - - - - - - - - - - + - 
 
5. 2000 + - - + + + - - - - - - - - - - - - + - 
 
 
1.Alertness 2.Aggressiveness 3.pilo erection 4.Grooming 5.Gripping 6.Touch 
Response 7. Motor Activity 8. Tremors 9.Convulsions 10.Muscle Spasm 11.Catatonia 
12.Muscle relaxant 13.Hypnosis 14.Analgesia 15.Lacrimation 16.Exophthalmos 
17.Diarrhea 18.Writhing 19. Respiration 20.Mortality 
+ Presence of Activity  
- Absence of Activity 
All the data were summarized in the form of (table-7) revealed that there was 
no abnormal signs and behavioural changes in all animals at the dose level of 
5,50,300,2000 mg/kg body weight administered orally, during the study period.  
There was no mortality observed after dosing of Tambira parpam upto 
2000mg/kg body weight during the study period of 14 days. This indicates that the 
LD50 of Tambira parpam is more than 2000mg/kg b.wt. 
There were no changes in skin and fur, eyes and mucous membranes of all 
animals.  The eating, drinking habit, sleep pattern, locomotion were normal in all 
animals and no changes in body weight as compared to control group. 
At the end of the 14 
the
 day, necropsy was performed and there was no 
abnormality seen in test groups as compared to control group during the examination. 
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28 Day Repeated Dose Oral Toxicity Study 
Food consumption of the animals significant difference in Food intake the test 
group  animals were observed when compared with control group during the study 
period. (Table 8), but they are within physiological limit. 
Table:8 Food (g/day) intake of albino rats exposed to  Tambiraparpam 
Dose 
(mg/kg/ 
day) 
 
 
1
st
 day 
 
7 
th
 day 
 
14 
th
 day 
 
21
st
 day 
 
28 
th
 day 
 
Control 
 
12.45±0.16 
 
13.15±0.16 
 
12.95±0.38 
 
12.8±0.21 
 
13.15±0.16 
 
 
LD 
 
 
12.8±0.21** 
 
14.8±0.21** 
 
16.95±0.38** 
 
19.65±0.38** 
 
21.3±0.32** 
 
MD 
 
 
12.45±0.16** 
 
14.5±0.54** 
 
16.8±0.54** 
 
18.8±0.54** 
 
19.95±0.71** 
 
HD 
 
 
13.15±0.16** 
 
15.95±0.71** 
 
18.15±1.25** 
 
19.95±0.71** 
 
21.65±0.71** 
 
SG 
 
 
12.98±0.38** 
 
15.5±0.54** 
 
17.8±0.54** 
 
19.1±0.54** 
 
20.65±0.71** 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05,**P<0.01 
Figure:3 
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28 Day Repeated Dose Oral Toxicity Study  
Water consumption the difference in Water intake of control and test group of animals 
observed during the study period. (Table 9), There was significant difference occurs 
in the group low and mid at 28 days compared with control group. 
Table:9 Water (ml/day) intake of albino rats exposed to Tambira parpam 
 
Dose 
(mg/kg/  
 
 
1 st day 
 
(ml/day) 
 
7 th day 
 
(ml/day) 
 
14 th day 
 
(ml/day) 
 
21 st day 
 
(ml/day) 
 
28 th day 
 
(ml/day) 
 
Control 
 
32.45±0.43 
 
33.65±0.38 
 
33.65±0.38 
 
34.3±0.32 
 
33.95±0.71 
 
 
LD 
 
 
32.95±0.38* 
 
32.95±0.38* 
 
33.65±0.38 
 
33.65±0.38* 
 
32.95±0.38** 
 
MD 
 
 
34.15±0.93* 
 
33.65±0.38 
 
32.95±0.38* 
 
33.65±0.38* 
 
32.95±0.38** 
 
HD 
 
34.3±1.86 
 
33.65±0.38 
 
33.65±0.38 
 
32.95±0.38 
 
32.95±0.38 
 
 
SG 
 
 
32.95±0.38 
 
33.65±0.38 
 
32.95±0.38*  
 
33.65±0.38* 
 
33.15±0.16* 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05,**P<0.01 
Figure:4 
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28 Day Repeated Dose Oral Toxicity Study  
Body weight of both control and test  dose group exhibited normal body weight 
throughout the study period. (Table 10) 
Table: 10 Body weight (g) changes of albino rats (male) exposed toTambira parpam 
Dose 
Mg/kg 
 
 
1
st
 day 
 
7 th day 
 
14 th day 
 
21 st day 
 
28 th day 
 
Control 
 
 
155±21.70 
 
163±21.70 
 
172±21.70 
 
181.66±21.45 
 
 
192±19.97 
 
LD 
 
159.3±21.07 
 
167.33±21.07 
 
178.33±20.5 
 
190.33±18.71 
 
200.66±18.14 
 
 
MD 
 
 
183±22.51 
 
191±22.51 
 
200.33±22.36 
 
211.33±20.64 
 
221.33±20.64 
 
HD 
 
 
181.66±8.50 
 
189.33±8.02 
 
199±7.21 
 
208±5.29 
 
217.33±5.50 
 
SG 
 
 
142.33±6.80 
 
150.33±6.80 
 
158.66±6.11 
 
170.66±6.11 
 
182.66±6.11 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05,**P<0.01 
 Figure:5 
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28 Day Repeated Dose Oral Toxicity Study  
Body weight of both control and test  dose group exhibited normal body weight 
throughout the study period. (Table 11) 
Table:11  Body weight (g) changes of albino rats (female) exposed to Tambira  
parpam 
Dose 
(mg/kg/ 
day) 
 
 
1 st day 
 
7 th day 
 
14 th day 
 
21 st day 
 
28 th day 
 
Control 
 
 
147±4.35 
 
156.66±4.16 
 
168±4.35 
 
179.33±8.08 
 
192.33±3.78 
 
LD 
 
 
143.33± 7.24 
 
153.66±7.09 
 
165.66±7.09 
 
176±6 
 
180.33±6.02 
 
MD 
 
 
147.66±7.09 
 
158.33±5.68 
 
169.66±5.85 
 
181.66±5.85 
 
194.33±4.72 
 
HD 
 
145.66±5.85 
 
154.66±6.80 
 
164±6.55 
 
175±6.55 
 
187.33±6.11 
 
 
SG 
 
 
145± 7.93 
 
154.33±7.09 
 
162.66±8.08 
  
174.33±8.02 
  
187±7.54 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05,**P<0.01 
Figure:6 
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28 Day Repeated Dose Oral Toxicity Study  
The results of the Haematological investigations conducted at the end of the study, 
the groups revealed slightly significant changes in levels of haematological 
parameters, when compared with control group, and post retrieval group 
haematological parameters towards normal, when compared with control group. 
(Table 12) 
    Table: 12 Effect of Tambira parpam on Haematological Parameters 
Parameter Control LD MD HD SG 
 
RBC 
(×10
6
µl) 
4.08±0.09 5.75±1.57 5.7±1.67 6.06±1.16* 6.28±0.64* 
WBC 
(×10
3
µl) 
8.93±0.48 13.31±8.20 10.65±3.15 12.98±3.13 10.8±2.10 
PLT 
(×10
3
µl) 
792.8±93.33 560±176.41* 771.6±127.12 641.6±148.2 743±101.30 
HGB 
(g/dl) 
12.5±0.74 13.81±1.28 11.81±2.42 12.8±1.54 11.66±2.32 
Neutrophils 
10
3
/mm
3
 
2.01±0.47 2.05±0.55 2.1±0.50 14.61±28.6 2.45±0.79 
Lymphocyte 
(%) 
76.4±1.52 75.56±10.59 73.01±6.84 83.58±5.60 77.41±4.33 
Monocyte (%) 3.18±0.11 2.41±0.82 14.35±28.8 3.51±1.19 2.51±0.90 
eosinophil’s 
(%) 
1.3±0.15 1.23±0.20 1.41±0.28 1.45±0.21 1.55±0.23 
Basophils 
(%) 
0.66±0.51 0.33±0.51 0.5±0.54 0.33±0.51 0.16±0.40 
MCH 
(pg) 
20.95±1.0 18.25±1.42 18.5±2.6 17.85±1.99* 16.41±2.55** 
MCV 
(fl) 
62.06±2.65 59.3±3.74 56.4±8.76 57.53±7.7 53.68±6.7 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05,**P<0.01 
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Figure: 7 
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Figure:9 
 
Figure: 10 
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Figure: 11 
 
Figure:12 
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28 Day Repeated Dose Oral Toxicity Study  
Biochemical investigations were conducted at the end of the study and the 
results were recorded. In test groups there was significant changes present in 
biochemical parameters, when compared with the control group. At the values were 
normal biological limits. (Table 13) 
     Table:13 Effect of Tambira parpam on Biochemical parameters 
Dose (mg/kg) 
 
 
Control 
 
LD 
 
MD 
 
HD 
 
SG 
Total 
cholesterol 
(mg/dl) 
 
111.26±1.16 
 
104.1±9.90 
 
126.8±25.0 
 
139.51±8.65** 
 
127.46±11.1 
 
 
HDL (mg/dl) 
 
60.5±4.08 
 
 
51.33±7.03 
 
62.5±7.28 
 
56±6.6 
 
66±6.35 
 
 
LDL (mg/dl) 
 
31.16±5.03 
 
30±9.81 
 
50.3±22.9* 
 
60.66±7.52** 
 
46.83±6.64 
 
 
VLDL (mg/dl) 
 
16.43±2.72 
 
22.7±4.39 
 
19.28±8.23 
 
21.71±3.52 
 
14.63±1.89 
 
Triglycerides 
(mg/dl) 
 
49.66±2.33 
 
49.6±16.30 
 
77.16±22.6 
 
94±27.5** 
 
37.5±12.5 
 
 Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05,**P<0.01 
Figure:13 
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28 Day Repeated Dose Oral Toxicity Study   
The results  of the renal functions test conducted at the end of study, test 
groups revealed significant changes in levels of renal parameters, when compared 
with control group, and post retrieval group Renal function parameters towards 
normal, when compared with control group.(Table 14) 
Table:14 Effect of Tambira parpam on Renal Parameters 
 
Dose(mg/kg) 
 
 
Control 
 
LD 
 
MD 
 
HD 
 
SG 
BUN(mg/dl) 
 
15.91±2.2 21.5±2.8** 19.33±2.94 20.1±2.48* 16.9±3.33 
Creatinine (mg/dl) 0.86±0.12 0.93±0.12 0.86±0.24 1±0.17 
0.75±0.22 
 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05,**P<0.01 
Figure:14 
 
  
 
 
 
 
 
0
5
10
15
20
25
BUN(mg/dl) Creatinine(mg/dl)
Effect of Tambira parpam on Renal Parameters 
Control
LD
MD
HD
SG
RESULT 
 
Preclinical Safety Evaluation  Of Tambira Parapm Page 79 
 
28 Day Repeated Dose Oral Toxicity Study    
The results of the liver function test conducted at the end of the study, test 
groups revealed significant changes in levels of liver parameters, when compared with 
control group, and post retrieval group Liver function parameters towards normal, 
when compared with control group  
 Table:15 Effect of Tambira parpam on Hepatic Parameters 
 
Dose(mg/kg) 
 
 
Control 
 
LD 
 
MD 
 
HD 
 
SG 
 
Total 
Bilirubin(mg/dl) 
 
0.48±0.15 
 
0.66±0.16 
 
0.58±0.21 
 
0.8±0.16* 
 
0.45±0.2 
 
SGOT(U/L) 
 
 
101±14.8 
 
96.6±49.1 
 
134.6±32 
 
143.6±12.0 
 
122±27.1 
 
SGPT(U/L) 
 
 
29.8±2.7 
 
55±7.5** 
 
53±7.1** 
 
52.5±6.9** 
 
 
36±10.6 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05,**P<0.01 
   Figure:15 
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28 Day Repeated Dose Oral Toxicity Study     
The Organ weight no difference in organ weight of control and test group 
observed after 28
th
 days repeated oral toxicity study period, and satellite group was 
sacrificed after 14 days of drug withdrawal.(Table 16) 
Table: 16 Organ Weight (g) Changes of Wister albino Rats Exposed to Tambira 
Parpam 
Organs Control Low dose Mid dose High dose Satellite group 
 
Heart 0.45±0.02 0.52±0.10 0.61±0.11 0.60±0.01 0.68±0.13 
 
Lungs 1.13±0.21 1.3±0.34 1.4±0.02 1.62±0.51 1.74±0.57 
 
Liver 7.24±1.77 7.12±1.12 6.98±0.11 7.12±1.65 7.43±1.13 
 
Rt. Kidney 0.73±0.07 0.78±0.41 0.74±0.43 0.75±0.20 0.74±0.13 
 
Lt. Kidney 0.79±0.09 0.78±0.07 0.75±0.01 0.73±0.19 0.75±0.15 
 
Spleen 0.47±0.21 0.44±0.08 0.45±0.02 0.53±0.13 0.48±0.10 
 
Brain 1.41±0.12 1.55±0.08 1.46±0.02 1.63±0.09 1.58±0.11 
 
Stomach 1.26±0.16 1.41±0.09 1.32±0.16 1.38±0.18 1.37±0.21 
 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05,**P<0.01 
Figure:17 
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28 Day Repeated Dose Oral Toxicity Study      
Histopathology of Heart                                             
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  Plate a 
 Nucleus appears prominent with a regular arrangement of fibers. No evidence 
of pyknotic nucleus. 
 No evidence of collagen deposition in the myocardium. 
Plate b 
 Normal network of myocardial fibres was observed 
 No evidence of atherosclerosis and thrombosis 
 Plate c 
 Nuclei of cardiomyocytes appears regular size and shape 
 Arrangement of cardiac myofibers was normal 
Plate d 
 Cardiac fibers appears normal with regular striations 
Plate e 
 The appearance of cardiomyocyte was normal with the dark nuclear region. 
The nuclei of muscle fibers appear central arrangement. 
 Myocardial tissue appears normal with orderly striated heart muscle fibers and 
a clear nuclear and muscle bands. 
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28 Day Repeated Dose Oral Toxicity Study     
                                                  Histopathology of Lungs 
Plate a. Control                                         Plate b. Low dose group 
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Plate a 
 Lung parenchyma appears normal with regular arrangement of alveoli and 
alveolar sac with no signs of lymphocyte infiltration and pulmonary fibrosis 
 No evidence of lymphocyte aggregation in deep airway layers 
Plate b 
 Normal lung parenchyma with regular airway histology was observed 
 No evidence of perivascular cuffing 
Plate c 
 No evidence of lymphocyte proliferation 
 Appearance of vascular sheath and perivascular regions are normal 
Plate d 
 No signs of airway secretion and bronchial secretion 
 Bronchial blood vessels and connective tissue appears normal with no signs of 
pulmonary oedema 
Plate e 
 Perivascular region appears normal, Alveolar septa and wall appeared to 
widen and normal 
 Lung parenchyma appears normal with regular arrangement of alveoli and 
alveolar sac with no signs of lymphocyte infiltration and pulmonary fibrosis. 
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28 Day Repeated Dose Oral Toxicity Study     
Histopathology of Liver 
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Plate a 
 Hepatocytic cytoplasm appears normal. The centrilobular hepatocytes appears 
normal with stained cytoplasm 
 No evidence of mesenchymal reaction on to the hepatic parenchyma. 
Plate b 
 Numerous hepatocytes appears with shrunken nucleus 
 No signs of nodular degeneration and cirrhosis. 
 No evidence of collagen (fibrosis) 
Plate c 
 Increased numbers of Kupfer cells were observed 
 Occasional migration of inflammatory cells 
Plate d 
 Diffused vascular changes were observed in the mid-zonal region 
 Hepatocytes appear variably pale with mild congestion on central vein 
 Mild discrete cytoplasmic vacuoles and rare foamy cytoplasm  were observed 
Plate e 
 Extensive periportal degenerative change was observed 
 Hepatocytes rarely projects dark pyknotic shrunken nuclei 
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28 Day Repeated Dose Oral Toxicity Study      
Histopathology of Stomach 
                 Plate a. Control                                 Plate b. Low dose group 
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Plate a 
 Mucosal wall appears normal with regular arrangement of connective tissue 
 Histology of gastric wall composed of normal mucosa, muscular mucosa, sub 
mucosa, muscularis propiria and adventitia 
Plate b 
 Intracytoplasmic zone of mucosa appears normal 
 Histology of gastric wall composed of normal mucosa, muscular mucosa, sub 
mucosa, muscularis propiria, and adventitia. 
Plate c 
 Light microscopic observation stomach reveals normal histology of gastric 
wall composed of normal mucosa, muscular mucosa, sub mucosa, muscularis 
propiria, and adventitia. No signs of ulceration were observed 
Plate d 
 The appearance of the glandular lumen was normal. Lamina propria appears 
normal with no evidence of infiltration and inflammation.  
Plate e 
 Light microscopic observation of both the sample reveals normal histology of 
rat gastric wall composed of mucosa, muscular mucosa, sub mucosa, 
muscularis propiria, and adventitia 
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28 Day Repeated Dose Oral Toxicity Study      
Histopathology of Spleen 
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Plate a 
 The appearance of red pulp and marginal sinus are normal. No abnormalities 
found in lymph nodes  
Plate b 
 Appearance of marginal sinus was normal 
 Lymphoid follicles appear normal. Marginal sinus (MS) of the rat and its sinus 
lining cells appear normal. Erythropoietic cells (EP) are scattered throughout 
the red pulp. 
Plate c 
 Germinal centre, Follicle and Central artery appears normal 
Plate d 
 Mild reduction in cellularity and size of the red pulp 
Plate e 
 Erythropoietic cells (EP) are scattered throughout the red pulp. No 
abnormalities found in the lymph node. 
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28 Day Repeated Dose Oral Toxicity Study      
Histopathology of Kidney 
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Plate a 
 Glomerulus (G) surrounded by a narrow capsular space and the parietal layer 
of Bowman's capsule. 
 Note the proximal convoluted tubules (P) and the distal convoluted tubules 
(D) 
 Epithelial lining on proximal convoluted tubule appears normal 
 The lumen of distal convolutes tubule and collecting duct was normal. 
Plate b 
 Presence of tubular cast was evident with widening proximal and distal 
convoluted tubule 
 Shrunken glomeruli with wide bowman’s space. 
Plate c 
 Swollen tubular basement membrane 
 The lining epithelial cells of the renal tubules shown pyknosis of the nuclei 
Plate  d 
 Section showed shrunken glomeruli (G) with widening capsular Bowman's 
space 
 Rare appearance of intercapillary sclerosis was observed  
Plate e 
 Glomerular degeneration with mild derangement in mesenchymal density 
 Alteration in thickness of proximal convoluted tubule  
 Mild tubular degeneration with increase bowman’s space 
 Renal tubule with the mild swollen epithelial cell. 
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28 Day Repeated Dose Oral Toxicity Study      
          Histopathology of Testis 
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Plate a 
 The presence of mature somatic cells projects the perfect histomorphology of 
testicular cells were observed.  
 Primary spermatocytes with a largely centred nucleus and dense chromatin 
were observed. 
Plate b 
 Normal Sertoli cell aligned properly on the basement membrane with oval 
dome shaped nucleus shows the normal morphology of the seminiferous 
tubule was observed. 
Plate c 
 Histo cytology of testicular tissue shows well-differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed. 
Plate d 
 The appearance of Leydig cells, interstitial tissue, seminiferous tubule, Sertoli 
cells, and spermatogonia were normal 
Plate e 
 The Presence of mature somatic cells projects the perfect histomorphology of 
testicular cells were observed. Primary spermatocytes with a large centred 
nucleus and dense chromatin were observed. 
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28 Day Repeated Dose Oral Toxicity Study      
Histopathology of Uterus 
                 Plate a. Control                                 Plate b. Low dose group 
 
              Plate c. Mid dose group                          Plate d. High dose group 
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Plate a 
 The appearance of endometrium, myometrium and uterine glands was normal.  
 Endometrial gland, epithelium, and blood vessels appear normal. 
Plate b 
 The arrangement of uterine layers such Endometrium and myometrium are 
normal with no signs of abnormalities. 
 Arrangement of stratum basal, functional and surface epithelium seems normal 
 Endometrial gland, epithelium, and blood vessels appear normal. 
Plate c 
 The arrangement of uterine layers such Endometrium and myometrium are 
normal with no signs of abnormalities. 
 Endometrial gland, epithelium, and blood vessels appear normal. 
Plate d 
 The arrangement of uterine layers such Endometrium and myometrium are 
normal with no signs of abnormalities. 
 The arrangement of stratum basal, functional and surface epithelium seems 
normal. 
Plate e 
 The appearance of endometrium, myometrium and uterine glands was normal.  
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Sub-acute toxicity Study 
                                                 Histopathology of Ovary 
                           
 
 
 
 
 
 
Plate a. Control                                            Plate b. Low dose group 
 
 
                           
 
 
 
 
 
   Plate c. Mid dose group                                       Plate d. High dose group     
 
 
 
             Plate e. Satellite dose group  
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Plate a 
 Histopathological analysis of ovary showing normal corpus luteum (CL) and 
Primordial follicles with few mature ovarian follicles with no signs of 
abnormality.  
Plate b 
 Sequential arrangement of granulosa cells around oocyte was normal and 
regular 
 Follicular cells, cytoplasm, and nucleus appears normal 
 Appearance of antral follicle, primary oocyte, and secondary follicles are 
normal 
Plate c 
 Histopathological analysis of ovary showing normal corpus luteum (CL) and 
Primordial follicles with few mature ovarian follicles with no signs of 
abnormality.  
Plate d 
 Sequential arrangement of granulosa cells around oocyte was normal and 
regular 
 Follicular cells, cytoplasm, and nucleus appears normal 
Plate e 
 Sequential arrangement of granulosa cells around oocyte was normal and 
regular 
 Follicular cells, cytoplasm, and nucleus appears normal 
 
 
 
 
 
RESULT 
 
Preclinical Safety Evaluation  Of Tambira Parapm Page 100 
 
28 Day Repeated Dose Oral Toxicity Study     
Histopathology of Brain 
               Plate a. Control                                             Plate b. Satellite group 
Plate a 
 Regular marginal alignment on the neurons with promising histology. Neuron 
is very intact and there were no signs of oedema or degeneration were 
observed. 
  Section of cerebellum shows distinct molecular and granular layer. Neuronal 
architecture appears normal with sufficient numbers 
 The arrangement of the neurons appears intact with no signs of degeneration 
or apoptotic changes.   
Plate b 
 Cortex region showed normal neurons with polygonal to round cell bodies 
containing dense cytoplasm. 
 Normal appearance of cerebral cortex and medulla with intact parenchyma   
 Neuronal cellular architecture appears normal with regular interneuronal 
space. 
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                                                 DISCUSSION 
The Tambira parpam is used for the treatment of Earl kuruku 
veekam(hepatomegaly),Nadukuvatham (Parkinson’s diseases),Maarpu selanthe 
(Breast tumour),Yonni putru (vaginal cancer),Gunmam(peptic ulcer),Pathavanmegam  
(filariasis) Naatpatta thalaivali (chronic headache)etc 
[9]
under Siddha  system  of  
medicine. One of the ingredients of this drug was Tambiram, has a long history in the 
treatment of peptic ulcer and cancers among Siddha doctors in the Tamilnadu.  
Literature Review reveals that there was no such research has been done on 
Thurusu sembu (Copper) parpam. As an initial step, in this present study, a part of 
standardization of this drug and its safety has been confirmed through  necessary 
analysis  and  Acute  & 28  days  Repeated  Oral  Toxicity studies as per OECD 
guidelines.
[7][8]
 
Standardization of the drugs means confirmation of its identity and 
determination of its quality and purity.
[ 39]
By way of standardization, metal-based 
drugs can be evaluated for their performances,  limitations,  optimal dosage,  
contraindications,  and applications.
[40]
 Stability parameters
[ 3 9 ]
such as Physical, 
Chemical for the herbo-mineral  formulations were carried out for the test drug also.  
Physico-chemical analysis (Table-1, 2) of Tambira parpam reveals that the drug 
appears Dark grey in colour and crystalline in nature. Its pH value was 8.97 Thus, 
this is a strong alkaline which is expected to have significant absorption in the in the 
stomach than in intestine.  The loss on drying at 105oC was 1.9160% w/w, which 
explains its moisture content leading to the decomposition of the plant materials. 
The Total Ash content and Acid Insoluble Ash were found to be 96.36% and 22.84% 
respectively. This explicates the purity of the test drug. Similarly, Water Soluble 
Extractive value and Alcohol Soluble Extractive value was found to be 5.56% and 
0.81% respectively which makes clear that more amount of active constituents can 
be extracted with water as a solvent than alcohol is a solvent. 
Qualitative analysis (Tables- 4,5,6) of Tambira parpam for Acid radicals, Basic 
radicals, and other constituents demonstrates the presence of Chloride, Phosphate, 
Iron, and Alkaloids. 
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The result of Atomic Absorption Spectrometric Studies (Table-7) of Tambira 
parpam for the determination of heavy metals proves that they are within the 
permissible limits as per WHO. The presence of Copper was found to be 11.2 ppm 
and others namely, Lead, Cadmium, Arsenic, and Mercury was below detectable 
limits. 
Thermogravimetric analysis of Tambira Parpam carried out at the maximum 
of 1000
0
C.The main objective of the study is to evaluate the decomposition and 
stability limit of the prepared formulation Tambira parpam. Prepared formulation 
Tambira parpam seems to be stable at the temperature varying from50 ºC to 800 ºC 
with no variation in the residual weight. The point of decomposition begins when the 
temperature increases beyond 800 ºC. Sharp deletion curve observed from 800 ºC to 
825 ºC and at this point suggested crystal transformation may be observed. Predicted 
denaturation may be due to atomic change at oxygen atom present within the sample. 
The weight of the final residual matter was observed as 3.307 mg with 75.14% of 
residual volume. The remaining portion (approximately 25%) contains organic 
compounds also. 
 The X-ray diffraction pattern of the of the prepared formulation Tambira  
Parpam reveals the presence of a major peak with 2- Theta value of 38.719 which 
exactly matches to the ICDD (International Centre for Diffraction Data) 80- 1916. 
ICDD 80-1916 corresponds to the crystalline pattern of copper oxide (CuO). Hence 
the reference matching material was confirmed as copper oxide (CuO). Major 
peaks observed in  Tambira parpam  with  2-theta  values of  35.49  and their 
corresponding intensities were 3492.The major peak observed in the reference 
matching material was 38.68 with the intensity value of 999. The  XRD  pattern of 
the test  (Tambira  Parpam)  exactly matches with the reference material CuO, 
which justifies the presence of stable and purified CuO in the formulation. From 
the result of the present XRD analysis, it  was concluded that the elemental 
composition of Tambira parpam confirms the presence of CuO at its stable state. 
Further copper being the major component of the formulation Tambira parpam.  
Analysis of Tambira parpam by Scanned Electron Microscopy revealed 
the size stabilization of particles on the process and the presence of nano-sized 
particles with a range of 10.17nm to 22.9 µm. Nano- sized particles can attach to 
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the cell surface and can diffuse readily inside the cells.  Thus, the size of the 
particle is able to influence the efficacy.  The particles are Spherical in shape with a 
smooth surface. The particles show the evenly distribution in the fields examined 
(Figure – 1&2). 
Analysis of Tambira parpam by Fourier transform infrared 
spectroscopy (FTIR)  revealed the Infrared absorption pattern of CuO stretching was 
observed in the region of 523.16 cm−1 to 691.53 cm−1.Sharp absorption peak 
observed in the region of 590.87 cm−1 indicates the IR spectral pattern of CuO. 
Absorbance peak at 1107.93 cm−1 corresponds to CuO vibration due to the metal 
cation. The broad absorption peak at 3367.73 cm−1 corresponds to O-H stretching 
which is bonded. Wide absorption peaks at 1645 cm−1 may be due to the presence of 
primary amino group and also due to the vibrational intensity of C=C group. 1404 
cm−1 corresponds to CH2 Bending. 1463 cm−1 corresponds to CH2 deformation. 
In Acute toxicity study (Table - 9), carried out as per OECD guideline 423, 
there was no treatment- related death or signs of toxicity developed in albino rats 
at dosage levels of 5mg, 50mg, 300mg and 2000mg/kg body weight throughout the 
study period. Further, no gross pathological changes have been seen in the 
internal organs of both control and treated groups. Thus, the LD50 value was found 
to be greater than 2000 mg/kg body weight. With reference to the Globally 
Harmonised System of Classification and Labelling of chemicals, Tambira parpam 
can be classified as category-5
[41]
 and this provides direct
 
relevance for protecting 
human and animal health. 
To ensure the safety of Tambira parpam, 28 days Repeated Oral 
Toxicity Study was also carried out as per OECD test guideline 407. Except for 
hyperactivity at the time of drug administration, no other signs of toxicity were 
noted.  After blood collection, all the animals were euthanized for gross pathological 
examinations of all major internal organs. The blood samples were sent to a lab 
for hematological and biochemical analysis.  The organs were weighed and 
preserved in 10% buffered formalin solution before sending for histopathological 
study. All the reports were statistically analyzed. 
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  Tambira parpam Significant difference in Food intake the test group animals 
were observed when compared with control group during the study period(Table8,9 & 
Figure3,4) but they are within physiological limit, and this study reveals that it does 
not adversely affect the basic metabolic processes of the experimental animals. The 
hemopoietic system serves as an important target for toxic chemicals and is a 
sensitive index for pathological conditions both in humans and animals. In 
Haematological parameters, it had been observed that WBC level was elevated after 
the administration of Tambira parpam at the high dose level (Table 12 & Figure 7, 8, 
9, 10, 11, 12). But the WBC level was within normal range in post retrieval group 
after 14 days of withdrawal of medicine.   Transaminases (SGOT and SGPT) are 
good indicators of liver function and biomarkers to predict the possible toxicity of 
drugs. Any elevation pertaining to these enzymes indicate their outflow into the 
blood stream due to damage in liver parenchymal cells. But, there was a marked 
increase in SGPT (Table – 15&Figure 15, 16) in high dose treated animals, when 
compared to control group, but it was also in normal range in Post retrieval group.  In 
the present study, there was no treatment-related abnormality in renal functions at 
all the animals (Table - 14& Figure14) and other biochemical parameters (Table 
13& Figure13) off Tambira parpam is treated animals were normal, when it is 
administered at higher dose level (400mg/kg). The therapeutic dose of Tambira parpam 
is 3mg/day for the human uses mentioned in Siddha text. This dose was very minimal 
compared to animal doses at low dose treated group (100 mg/kg b.wt)  
The histopathological study, organs such as brain, heart, kidney, liver, 
lungs, spleen and stomach were taken. In organs of Control group, no abnormality 
was detected. In organs of Group III and IV, glomerular degeneration with mild 
derangement in mesenchymal density, alteration in thickness of proximal convoluted 
tubule mild tubular degeneration with increase bowman’s space, renal tubule with the 
mild swollen epithelial cell were detected.  
The extensive periportal degenerative change was observed. Hepatocytes 
rarely project dark pyknotic nuclei were observed in high dose groups. There’s no 
pathological changes occur in other organs such as liver and renal, but post retrieval 
group of animals it not show any abnormalities during the study period. 
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       SUMMARY 
 
Tambira parpam is used for the treatment of Earl kuruku veekam 
(hepatomegaly), Nadukuvatham (Parkinson’s diseases), Maarpu selanthe (Breast 
tumour), Yonni putru (vaginal cancer), Gunmam (peptic ulcer), Pathavanmegam  
(filariasis) Naatpatta thalaivali (chronic headache)&etc as mentioned in the Siddha 
literature. The raw drugs were procured from farms and shops. They were 
identified and authenticated by Botanist, National Institute of Siddha. The Raw 
drugs were purified and the medicine was prepared as mentioned in the Siddha 
literature.  On organoleptic examination, the finished product seems to be grey in 
colour and crystalline in nature. 
In physicochemical analysis of Tambira parpam, the pH was found to be in 
8.97% with a loss on drying at 105
0
C of 1.9160 % w/w.Total Ash value, Acid 
insoluble Ash value, Water, and Alcohol Soluble Extractive values reveal the purity 
of the test drug. Qualitative Analysis of Tambira parpam demonstrates the 
presence of Chloride, Phosphate, Iron, and Alkaloids. 
Results of AAS confirm that the heavy metals were within the permissible 
limits in Tambira parpam, but copper content was present in 11.139 ppm level. SEM 
result confirms the presence of nano-sized, spherical shaped particles ranging 
between 10.17nm to 22.9µm, with a smooth surface in evenly distribution. 
 Thermogravimetric analysis of Tambira Parpam Weight of the final 
residual matter was observed as 3.307 mg with 75.14% of residual volume. The 
X-ray diffraction pattern of Tambira Parpam result of the present XRD analysis 
it was concluded that the elemental composition of Tambira parpam confirms the 
presence of CuO at its stable state. Further, copper is the major component of the 
herbo-mineral formulation Tambira parpam in oxide form. 
 
Analysis of Tambira parpam by Fourier transform infrared 
spectroscopy (FTIR)  revealed the Infrared absorption pattern of CuO stretching 
was observed in the region of 523.16 cm−1 to 691.53 cm−1 they a functional group 
of CuO, O-H group, Primary amino group and C=C group, CH2 Bending and CH2 
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deformation also observed in FTIR. This study also confirmed the presence of CuO 
in Tambira parpam. 
The toxicological evaluations were conducted as per OECD guidelines   
423 & 407 for safety evaluation of Tambira parpam . In acute toxicity study, no 
signs of toxicity and mortality were observed throughout the study period up to 
the dose of 2000mg/kg body weight. Thus, the LD50 value of Tambira parpam 
was found to be greater than 2000 mg/kg body weight and classified as Category 5 
[38]
 
In 28days Repeated dose Oral Toxicity Study, there was no significant 
changes in behavioral signs,  food intake,  water intake,  Lipid Profile, Renal 
parameters hematological parameters (except WBC), and Hepatic parameters 
except that of SGOT and SGPT. The liver function test conducted at the end of the 
study, test groups (Low, Mid, High dose) revealed significant changes in level of 
liver parameters, when compared with control group animals. But the SGPT level of 
post retrieval animals were Normal limits compared to control group. There is no 
significant changes occurs in Satellite group. In Post retrieval group, both the 
Haematological and Hepatic parameters were observed in normal  range. 
In organs of Control group, no abnormality was detected. The 
histopathological changes were noted in liver and renal tissue at the dose level mid 
and High dose treated group. At the same time the normal histological structure 
present in post retrieval group of animals.     
 The above studies explained the qualitative of drug and presence of CuO in 
the study drug. They nanoparticles were also excises in the test drug by studding 
various analytical methods. From the safety study revealed that the high dose treated 
animals had some minimal pathological changes, but post retrieval animals had 
normal physiological parameters. So the drug may be eliminated after completion of 
the treatment period of the animals. These findings were crave the safety uses of the 
metallic preparation used in Siddha system of medicines.    
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                                                  CONCLUSION 
Tambira parpam had been used by Siddhars for long time to treat various 
diseases such as Peptic ulcer, Breast tumour, Parkinson’s diseases, hepatomegaly, 
vaginal cancer. Since Copper is present in Oxide form in Tambira parpam, which is 
observed by the quantitative analysis, the drug can be easily absorbed in intestine. 
Acute toxicity study shows that the test drug can be used up to the dose of 
2000mg/kg bodyweight as a single dose. As per Siddha literature, the test drug was 
used as a minimal dose medicine. Though administration of 200 mg/kg b.wt and 400 
mg/kg b.wt Tambira parpam produces mild elevation of WBC and SGPT in Group 
Mid and High dose  group of animals, no notable abnormalities were observed in 
Satellite group of animals. Hence, we conclude that the dosage of Tambira 
parpam, 1.5mg twice a day narrated  in Theran yemaha venba 
[10]
 is a safer 
therapeutic dose for uses of human. The author hopes that this study will be a 
footprint to future research  of Chronic toxicity study, Carcinogenicity, 
Teratogenicity regarding Tambira parpam. 
 
 
REFERECE 
 
Preclinical Safety Evaluation  Of Tambira Parapm Page 108 
 
REFERENCE 
1.  S.P.Ramachanthiran, Sattimuni Gnanam, published  by Chennai: 
Thamarai Noolagam,  1
st 
Edition 1999,Pg No:.58,59 
 
2.  Yugi Munnivaidhiya Sinthamani 800, Published  by Chennai: Thamarai  
           Noolagam, 2
nd 
Edition 2013; Pg. No.: 2. 
 
3. Malayandi, Suubramaniyam, “Epigraphical and rock-shelter painting       
      Evidence for The Siddha Medical Studies during the pre-historic and proto-
historic periods”, Heritage of the Tamil Siddha Medicine, Eds Subramanian, 
S.V.& Madhavan,V.R.,page No:, 27 
 
4. Dr.K.S. Uthamaraayan, Thotrakkirama Aaratchium Siddha   
     MaruthuvaVaralarum, published by: Indian medicine and homeopathy, 
Chennai 106; 4
th
 Edition 2008, Pg.no:355. 
 
5. N.Kandaswamy pillai, History of Siddha Medicine,Published  by: Indian  
      Medicine and homeopathy, Chennai 106; 2
st
 Edition 1998, Pg.no:1-18. 
 
6. Muralidass S.D,Suganya R,Hariharan S, Vasudevan R, Shree Devi M.S,  
     Chemical characterization of herbo-mineral Siddha formulation Kara Sooda 
Sathu Parpam,International journal of Ayurveda and Pharma Research 
October 2015,Vol-3.  
 
7. OECD: Guidelines for the Testing of Chemicals/Section 4: Health Effects  
      Test   No. 423: Acute Oral toxicity - Acute Toxic Class Method. Paris, 
France:    Organization for Economic Cooperation and Development; 
2002. 
 
8. Organization for Economic Cooperation and Development; Guidelines 
for the Testing of Chemicals/Draft Updated Test Guideline 407: 
Repeated Dose 28-Day Oral Toxicity Study in Rodents. 2008. 
 
9. Dr.  R.  Thiyagarajan  LIM. Gunapadam Thathu Jeeva Vaguppu Sixth  
      editon2006, Published by Chennai: Directorate of Indian Medicine and 
Hoemopathy; (Pg. No.: 2, 3,144-161) 
 
10. Theriyer Yamaga Venba, Published by: Indian medicine and homeopathy,  
      Chennai-106; 2
nd
 Edition 2003, Pg.no:216-237 
 
1 1 .  S.P. Ramachandiran ,Aagathiyer 12000 Muthal Kaandam, Published by       
 Chennai: Thamarai Noolagam; 2
nd 
Edition 1995 Pg. No.: 57. 
REFERECE 
 
Preclinical Safety Evaluation  Of Tambira Parapm Page 109 
 
1 2 .  S.P. Ramachandiran,  Bogar Nigandu  1200,  1st Edition,  published  by   
       Chennai: Thamarai Noolagam, 1999; Pg. No.: 72. 
 
13.  Vaidhiyarathinum Jege V.Balaramaya,Vaath Vaidhiyathuku Aathi, Siddha    
        Maruthuva Nool thirattu 1 
st
 part, Published by: Kanal Veliyedu, Chennai-   
       04, 1
st
   Edition 2015, Pg No: 558,568,570,571,582. 
14.  Romaresi Vaidhiyam-500, published  by Chennai: Thamarai Noolagam,  2nd      
     
Edition 2004; Pg. No.: 45-47.      
                             
15. S.P. Ramachandiran ,Yagoppu Panchamithiram-300,published by    
   Chennai:Thamarai Noolagam; 2
nd
   Edition 2000 Pg.No.:31, 40, 47, 
48,59,62,67. 
 
16. Anonymous, Sarakku Suthi Sei Muraigal, 1st Edition, Published by Indian  
      Medicine and homeopathy, Chennai 106; 1
st
 Edition 2008, Pg.no:291 
 
17. R.C.Mohan, Agasthiyer Maagadravagam 800, 2nd Edition 2004, published   
by Chennai:Thamarai Noolagam; Pg. No.: 81. 
 
18. Nanthiser karukkidai 300, published by Chennai: Thamarai Noolagam,  2
nd     
     Edition 2001; Pg. No.: 87. 
19. R.C.Mohan, Pathinen Siddargal Vaidhiya Sillaraik Koovai-2 Part, 2
nd    
      Edition 2005, published by Chennai: Thamarai Noolagam; Pg. No.: 291 
 
20. S.P.Ramachanthiran,Yoga Gana Sasthirathirattu/7,  published  by   
    Chennai:Thamarai  Noolagam,  1
st 
Edition1996;Pg. No.:105. 
 
21. Pathartha Gunavilakkam Thathu vaguppu, published by:B.Rathina  
       Nayagar&sons Chennai-79,  Pg No.121. 
 
22. Pogar Kurunthirattu 300 
 
23. Thirumoolar Vaidhiyam 
 
24. Dr.T.Anathan,Dr.S.Jega jothi Pandiyan,Dr.K.Meenatchi Sunthramoorthy,   
      Theran  Sekarappa,:published by,Siddha maruthuva maiya Aaratchi   
      Neliyam, Arumbakkam, Chennai-106 1st Edition2010;Pg No ;216-219 
 
25. K.S Murugesamuthaliyer ,Theran Maruthuva Paratham, 
 
REFERECE 
 
Preclinical Safety Evaluation  Of Tambira Parapm Page 110 
 
26. K.R. Namachivaya Rajayogi,Agasthiyer Nayanavethe-500, 2
nd  
Edition    
      1935,published by:  Shree Sathu Rathina Satguru Puthagasaalai, Chennai-
1,Pg No.:   20,56,58,59,66-68,72-77. 
 
27. S.P.Ramachanthiran,Oorvasi Rasavatha Sidka, published   by Chennai:           
      Thamarai Noolagam, 2
nd 
Edition2010 1997, Pg No; 223   
 
28. Pulipanai Vaidhiyam-500, Published by Chennai: Thamarai Noolagam,2
nd    
     
Edition 1999; Pg. No.: 58, 59. 
 
29. Dr.Vasudevan,Textbook of Biochemistry for Medical   
      Students,Published   by:Jaypee Brothers,New Delhi, 5
th 
Edition 2007,Pg   
       No:.327,328 
   
30. U. Satyanarayana, U.Chakrapani, Biochemistry, Published by:Arunabha Sen   
        Books and Allied (P) Ltd, Kolkata-09, 3
nd 
Edition 2008, Pg No: 416.417. 
 
31. Dr.V.Balasubramanian,Chemistry, Published  by Directorate of School 
       Education on behalf of the Govet,Tamil Nadu. 2
nd 
Edition 2011. 
 
32. Dr.Mohammed Amanalla,Medical Biochemistry and  
      Biotechnology,Published by:New Central Book Agency London, 1st   
       Edition 2011,Pg No:209,210 
 
33. Hans marquardt Siegfried G.Schafer Ronger Mcclellan, Frank     
      welsch,Toxcology, Published  by: Academic press London,1st Edition   
      1997, Pg No: 772-775 
 
34. Dr.K.S,Narayana Reddy,The Essentials of Fornsic Medicine and Toxicology,      
      Publish by: K.Suguna Devi, Malakpet, Hyderabad-036,13
th 
Edition 2011,Pg     
      No: 500,501. 
 
35. Dr.D.R.Lohar,Protocol for Testing Ayurvedic,Siddha and Unani Medicines,  
      Published by:  Government of India Department of AYUSH (PLIM Guideline) 
 
36. Standard Methods for the Examination of water and wastewater, Published by:  
      American Puplic Health Association (APHA) 18
th
  Edition 1992.   
      Washington.DC 2005. 
 
37. Coats,A.W.Redfern,J.P.(1963).”Thermogravimetric Analysis: A Review”.   
      Analyst. 88(1053) 906924.Bibcode:1963 Ann..88...906C. doi: 10.1039/AN   
      9638800906  
REFERECE 
 
Preclinical Safety Evaluation  Of Tambira Parapm Page 111 
 
38. Jump up Tikhonov, N.A.Arkhangelsky, I.V.Belyaev,S.S.Matveev,A.T.(2009).           
      “Carbonization of polymeric nonwoven materials”.Thermochimica Acta. 486:  
      66-   70.doi:10.1016/j.tca.2008.12.20  
 
39. Achana A. Bele et al., Standardization of herbal drugs: An overview;  
      International Research Journal of Pharmacy, 2011, 2(12), 56-60  
 
40. Vandana Garg et al., Facts about standardization of herbal medicine: a review;   
      Journal of Chinese Integrative Medicine, Oct. 2012, Vol. 10, No. 10   
 
41. OECD guideline for testing of chemicals, Acute Oral Toxicity Acute Toxic   
      Class Method; 2001, Annexure 3, Pg. No.:14 
 
42. Pandit. K.S. Murugesa Muthaliyar, Dr. Pon. Kurusironmani, Nanju Murivu     
    Nool 4
th 
Edition,   published   by   Chennai:   Department   of   Indian     
     Medicine   and Homoeopathy; 1933; Pg. No.: 62 
 
43. Robert.S.Mccuskey and David L. Earnest,Comprehensive        
      Toxiocology,Hepatic and Gastrointestinal Toxicology, Published   
       by:British    Library cataloguing in publication data , 1
st 
Edition1997,Pg  
       No: 390-394. 
 
44. John C. Bloom, Comprehensive Toxicology, Toxicology of the   
     Hematopoietic System. 
 
 
 
  
 
 
ANNEXURE 
                      
 
 
ANNEXURE 
 
Preclinical Safety Evaluation  Of Tambira Parapm  Page 112 
 
ANNEXURE 
 The following certificate are enclosed 
 Research Methodology Certificate 
 IAEC Certificate 
 Authentication Certificate 
BONAFIDE CERTIFICATE 
Certified that I have gone through the dissertation submitted by  
Dr. K. Anbarasan (Reg.No: 321416201) a student of final year M.D(s), Branch-VI, 
Department of Nanju Noolum Maruthuva Neethi Noolum, National Institute of Siddha, 
Tambaram Sanatorium, Chennai - 47, and the dissertation work has been carried out by the 
individual only. This dissertation does not represent or reproduce the dissertation submitted 
and approved earlier. 
Place: Chennai - 47    
Date:   
 
 
   
 
 
 
 
Name and Signature of the Guide,   
Department of  Nanju Noolum   
Maruthuva Neethi Noolum,    
National Institute of Siddha,   
Tambaram Sanatorium, 
Chennai - 47. 
Name and Signature of the HOD (i/c), 
Department of  Nanju Noolum  
Maruthuva Neethi Noolum,  
National Institute of Siddha, 
Tambaram Sanatorium,  
Chennai - 47. 
  
 
 
 
 
 
 
 
Name and Signature of the Director, 
National Institute of Siddha,   
Tambaram Sanatorium,   
Chennai - 47. 
 
 





